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Abstract
New drugs and molecular targets are urgently needed to address the emergence and spread of 
drug-resistant tuberculosis. Mycobacterium tuberculosis (Mtb) inosine 5’-monophosphate 
dehydrogenase 2 (MtbIMPDH2) is a promising yet controversial potential target. Inhibition of 
MtbIMPDH2 blocks the biosynthesis of guanine nucleotides, but high concentrations of guanine 
can potentially rescue the bacteria. Herein we describe an expansion of the structure-activity 
relationship (SAR) for the benzoxazole series of MtbIMPDH2 inhibitors and demonstrate that 
minimum inhibitory concentrations (MIC) of ≤ 1 μM can be achieved. The antibacterial activity of 
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the most promising compound, 17b (Q151), derives from inhibition of MtbIMPDH2 as 
demonstrated by conditional knockdown and resistant strains. Importantly, guanine does not 
change the MIC of 17b, alleviating the concern that guanine salvage can protect Mtb in vivo. 
These findings suggest that MtbIMPDH2 is a vulnerable target for tuberculosis.
Table of Content graphic
INTRODUCTION
The worldwide burden of tuberculosis is staggering: more than 1 million deaths and 10 
million new cases occur each year (https://www.cdc.gov/tb/statistics/default.htm, accessed 
5/21/2017). Approximately one third of the world’s population is infected with the causative 
agent Mycobacterium tuberculosis (Mtb), many with latent infections that can recrudesce if 
the patient becomes immunosuppressed. Treatment requires administration with isoniazid, 
rifampicin pyrazinamide and ethambutol for two months followed by an additional four 
months with isoniazid and rifampicin. However, almost 0.5 million cases involve Mtb strains 
that are resistant to isoniazid and rifampicin, further complicating treatment. Extensively 
drug resistant strains have also emerged that are resistant to at least isoniazid and rifampicin, 
a fluoroquinolone, and any one of the second-line injectables, capreomycin, kanamycin and 
amikacin. Frustratingly, as illustrated by the newly approved tuberculosis drugs bedaquiline 
and delamanid 1, resistance can emerge just a few years after introduction of a new therapy, 
underscoring the critical need for new drugs, drug targets, and drug regimens to improve 
tuberculosis treatment and combat the relentless evolution of resistance.
Inosine 5’-monophosphate dehydrogenase (IMPDH) is the enzyme that catalyzes the NAD+-
dependent conversion of inosine 5′-monophosphate (IMP) to xanthosine 5′-monophosphate 
(XMP). This reaction is the first and the rate limiting step in the de novo biosynthesis of 
guanine nucleotides and therefore controls the size of the guanine nucleotide pool.2 IMPDH 
is an attractive target for the development of new antibiotics due to the essential role of 
guanine nucleotides in DNA and RNA synthesis, signal transduction, energy transfer, 
glycoprotein biosynthesis and many other processes involved in cell proliferation.3 Mtb has 
three genes, designated as guaB1, guaB2 and guaB3, which encode IMPDH homologs. Only 
guaB2 is essential, 4–6 and only guaB2 encodes an active IMPDH (MtbIMPDH2).7 The 
proteins encoded by guaB1 and guaB3 are each missing key catalytic residues and neither 
display IMPDH activity 7. The functions of these proteins are currently unknown.
MtbIMPDH2 is a controversial target for tuberculosis. Several small molecule inhibitors of 
MtbIMPDH2 have been identified that display antibacterial activity in vitro and in 
macrophages 7–13, but as yet no compounds have been reported with activity in animal 
models of tuberculosis. Recently, Park et al. suggested that high levels of guanine (200–2000 
μM10) in the lungs of infected rabbits and humans can protect bacteria from MtbIMPDH2 
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inhibitors,10 calling into question the vulnerability of this target. However, the availability of 
free guanine for salvage is by no means certain since these concentrations exceed the 
solubility limit. More promisingly, Singh et al. constructed a conditional knockout of guaB2 
in Mtb and found that depletion of MtbIMPDH2 is rapidly bactericidal in vitro.11 They also 
showed that silencing of MtbIMPDH2 expression prevented infection in mice 11, consistent 
with the lower levels of guanine found in mouse tissue (7–20 μM 10). On the basis of these 
findings, Singh et al. concluded that this enzyme is indeed vulnerable.11
IMPDH also appears to have moonlighting functions of unknown physiological 
consequence, which further complicates the question of whether it is a vulnerable target. The 
protein contains a regulatory CBS subdomain in addition to the catalytic (β/α)8 domain. 
CBS domains bind nucleotides and modulate the activity of other enzymes and channels 14. 
However, deletion of the CBS subdomain does not affect the activity of the catalytic domain 
in IMPDH 15–18. The CBS subdomain binds ATP and/or GTP depending on the particular 
IMPDH 19–22. These interactions modulate the oligomerization of tetramers to form 
octamers and higher order structures in vitro, with modest effects on enzymatic activity 
19–22
. The physiological relevance of ATP/GTP binding and these higher order structures is 
uncertain. Most interestingly, deletion of CBS subdomain dysregulates the purine nucleotide 
pools in E. coli, leading to the toxic accumulation of ATP and other adenine nucleotides 
23, 24
. IMPDH binds nucleic acid and can act as a transcription factor in eukaryotes, and this 
activity is mediated by the CBS subdomain 25–27. IMPDH also interacts with numerous 
other proteins in bacteria, including the ribosome, RNAP, amino acyl tRNA synthetases, 
penicillin binding proteins, uridylate kinase, PRPP synthetase, adenylosuccinate synthetase 
and DNA helicase 28, 29. Neither the sites nor the physiological consequences of these 
interactions have been elucidated. Therefore it is possible that the essentiality of guaB2 in 
Mtb derives from a moonlighting function rather than enzymatic activity. Moreover, the 
physiological consequences of enzyme inhibition may well be different from protein 
depletion, which downregulates both enzymatic and moonlighting activities 30. More potent 
MtbIMPDH2 inhibitors are required to resolve this conundrum and determine the 
vulnerability of Mtb infections to IMPDH inhibition 31.
We have developed triazole (A-series), benzimidazole (C-series), phthalazinone (D-series), 
4-oxo-[1]benzopyrano[4,3-c]pyrazole (N-series), urea (P-series) and benzoxazole (Q-series) 
inhibitors of prokaryotic IMPDHs, including MtbIMPDH2 9, 32–40. These inhibitors exploit 
the highly diverged cofactor binding site, which explains their selectivity for bacterial over 
eukaryotic orthologs of IMPDH 9, 17. Individual members of the A, D, P and Q-series 
display antibacterial activity against Mtb as well as other pathogens 9, 41, 42. The best Q 
compound, 3 (Figure 1A), was a potent inhibitor of MtbIMPDH2 (Ki,app = 14 nM) and 
displayed moderate antibacterial activity (MIC = 6.3 and 11 μM in minimal GAST/Fe and 
rich 7H9/ADC/Tween media, respectively). The values of MIC increased 3 to 7-fold in the 
presence of guanine, suggesting that antibacterial activity resulted from the on-target 
inhibition of MtbIMPDH2.
Herein we report an expansion of the structure-activity relationship (SAR) for the Q-series 
of MtbIMPDH2 inhibitors and improved antibacterial activity. Importantly, antibacterial 
activity is not reduced in the presence of guanine for the most potent compounds. 
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Nonetheless, antibacterial activity appears to derive from the inhibition of MtbIMPDH2 as 
demonstrated by conditional knockdown and resistant strains. These findings suggest that 
MtbIMPDH2 is indeed a vulnerable target.
RESULTS AND DISCUSSION
Design strategy.
IMPDHs are a square planar homotetramers, with each monomer composed of two domains, 
the catalytic domain and a smaller domain containing tandem cystathione β-synthetase 
(CBS) motifs.43 The physiological role of the CBS domain is unknown. Deletion of this 
domain does not impact enzymatic properties or tetramer formation, but does improve 
solubility and crystallization. The crystal structure of the CBS deletion variant of 
MtbIMPDH2 (MtbIMPDH2ΔCBS)9 in complex with IMP and inhibitor 3 reveals that the 
aromatic ring of the 2,3-dichloroaniline is involved in a π- π interaction with the purine base 
of IMP, whereas the amide participates in an ionic-dipole interaction of the NH with the 
carboxylate of Glu458 and a hydrogen bond of the amide carbonyl with a water molecule 
(Figure 1B). The nitrogen atom of the 1,3-benzoxazole interacts with a water molecule that 
also engages the main chain nitrogen and oxygen atoms of His286. Moreover, the 4-pyridyl–
1,3-benzoxazole moiety of 3 binds in a hydrophobic pocket formed by Val60, Pro61, and 
Tyr487 and the pyridyl nitrogen atom interacts with the backbone carbonyl of Ser57 via a 
water network.9 This pocket is not present in human IMPDHs, explaining the selectivity of 
the compounds for bacterial IMPDHs. Note that the two sulfonamide inhibitors in Figure 1C 
do not extend into this pocket, perhaps explaining the higher affinity and selectivity of the Q 
compounds. 10, 11
Using this information, we explored several strategies to expand the SAR of the Q-series 
(Figure 2): (1) modifications to the pyridine or replacement of the 4-pyridyl with a phenyl 
containing various substituents that can interact (e.g. via hydrogen bonds and ionic-dipole 
interactions) with the side chain of Arg290; (2) modification of the 2,3-dichloroaniline with 
2,3-difluorophenyl ethers to enhance cell permeability or phenyl ethers containing 
hydrophilic groups capable of forming interactions with IMP and Glu458; (3) modifications 
of the amide group via replacement with a thioamide or amine to further explore interactions 
with Glu458; (4) replacement of the benzoxazole with a imidazo[1,2-a]pyridine; (5) 
insertion of a methylene linker between the benzoxazole and phenyl that was used as a 
pyridine replacement. Chemistry. The synthesis used to generate ether linked Q-series 
derivatives is illustrated in Scheme 1. Arylbenzoxazoles 4 were directly synthesized by 
oxidative cyclization methods using 2-amino-4-nitrophenol and aldehydes in the presence of 
activated carbon (Darco KB) under an oxygen atmosphere. The nitro group was reduced 
using Pd/C under 1 atm hydrogen to give 5-amine-2-arylbenzoxazoles 5. Enantiomerically 
pure phenyl ethers 6 were synthesized from (+)-methyl D-lactate and the corresponding 
phenol using Mitsunobu reaction conditions. The esters 6 were hydrolyzed to the 
corresponding acids 7, and then coupled with various 5-amine-2-arylbenzoxazoles in the 
presence of EDC·HCl in DMF to yield 8.39 Furthermore, 8 (Ar = 4-OMePh, R = 2,3-diCl) 
was treated with Lawesson’s reagent under standard conditions to generate thioamide 9 
quantitatively. Ester 6a was also treated with 1M DIBAL-H in DCM at −78 ºC to generate 
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aldehyde 10, which was subjected to reductive amination using 5 (Ar = 4-OMePh) and 
sodium triacetoxyborohydride in DCM to provide amine 11.
The synthesis of an imidazo[1,2-a]pyridine analogue started by allowing 5-nitropyridin-2-
amine to react with an α-bromoketone in the presence of NaHCO3 in ethanol to give 12. 
Nitro group reduction using SnCl2 in ethanol followed by coupling with carboxylic acid 7 
(R = 2,3-diCl) generated imidazo[1,2-a]pyridine 13.
The synthesis of a derivative with a methylene linker between the benzoxazole and the 
benzene was undertaken. 2-Amino-4-nitrophenol was coupled with a 1,1-dibromoethylene 
derivative using DABCO in NMP at 100 ºC to generate 14. The nitro group was reduced 
using 10% Pd/C under a hydrogen atmosphere and the resulting amine was coupled with 7 
(R = 2,3-diCl) using EDC·HCl in DMF to yield 15.
Enantiopure N-arylated benzoxazole derivatives were synthesized using copper catalyzed 
Ullman type reactions. L-alanine was treated with aryl iodides in the presence of cesium 
carbonate and CuI in DMF for 24 h to provide the N-arylated amino acids 16a-b.39 Attempts 
to couple these materials with 5 (Ar = 4-CNPh) using EDC·HCl failed. However, using 
HATU as the coupling reagent in DMF resulted in formation of 17a-b.
Scheme 2 depicts the functional group transformations to various substituents attached to the 
benzoxazole aryl group. Compounds 8i and 8j were subjected to alkylation reactions with 
ethyl 2-bromoacetate in the presence of K2CO3 and DMF to give 18a and 18b, respectively. 
These compounds were hydrolyzed using LiOH in THF:MeOH (1:3) to yield 19a and 19b, 
respectively. Carboxylic acid 19a was also converted to ester 20 using propargyl bromide 
and K2CO3 in dry DMF. Ester 8h was also converted to an array of derivatives. For example, 
it was treated with hydroxylamine hydrochloride to provide the corresponding hydroxamic 
acid 21. Base catalyzed ester hydrolysis of 8h in MeOH:THF:H2O (3:1:1) yielded 
carboxylic acid 22. Finally, ester 8h was converted to hydrazide 23 using hydrazine hydrate 
in EtOH, followed by treatment with carbonyl diimidazole (CDI) in the presence of DIPEA 
in DMF yielding 1,3,4- oxadiazolone 24.
Scheme 3 illustrates the synthesis of an array of derivatives via functional group 
transformation of 8f. For example, 8f was treated with hydroxylamine hydrochloride in 
absolute ethanol in the presence of triethylamine to afford hydroxamidine 25, which upon 
treatment with CDI and DIPEA gave 1,2,4-oxadiazolone 26. The tetrazole derivative 27 was 
prepared by treatment of 8f with sodium azide in the presence of ammonium chloride in dry 
DMF. Primary amide 28 was generated by treating 8f with t-BuOK in t-BuOH.45 Finally, 8f 
was treated with NiCl2·6H2O and NaBH4 in the presence of Boc2O in MeOH:THF to give 
the Boc protected primary amine, which was deprotected using trifluoroacetic acid in DCM 
to provide 29.46
The synthesis of 2-pyridone derivative 30 was carried out by treating 8b with LiCl and p-
toluenesulfonic acid in anhydrous methanol (Scheme 4). The pyridyl of 8a was oxidized 
using m-CPBA in DCM to give the corresponding pyridine N-oxide 31. The nitrile in 8u 
was reduced using NiCl2·6H2O and NaBH4 then protected as the corresponding t-butyl 
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carbamate. Removal of the protecting group using trifluoroacetic acid in DCM provided 
amine 32. The benzyl ether of 8v was removed by hydrogenolysis in presence of Pd/C under 
a hydrogen atmosphere to yield 33.
Finally, the synthesis of a benzoxaborole analogue is depicted in Scheme 5. A Mitsunobu 
reaction between 2-bromo-3-hydroxybenzaldehyde and (+)-methyl D-lactate was carried out 
in the presence of PPh3 and DEAD in THF to give 34. This aldehyde was treated with 
NaBH4 in ethanol to generate the primary alcohol, which was protected as the corresponding 
methoxymethyl ether 35 using methoxymethyl chloride (MOMCl) and DIPEA in DCM. 
Boronylation of the aryl bromide was carried out using bis(pinacolato)diboron in the 
presence of KOAc and a catalytic amount of Pd(Ph3P)2Cl2 in 1,4-dioxane to give 36.47 Ester 
hydrolysis followed by amine coupling with 5 (Ar = 4-CNPh) in the presence of EDC·HCl 
in DMF and then treatment with 6N HCl in THF gave benzoxaborole 37.
Evaluation of MtbIMPDH2 inhibition.
We previously described the MtbIMPDH2ΔCBS inhibition and antibacterial activity of 
benzoxazole (Q) based inhibitors.39 The most promising compounds, 2 and 3 (Figure 1A), 
had Ki,app values of 76 nM and 14 nM, and MIC values of 16 μM and 12 μM, respectively. 
MtbIMPDH2ΔCBS was expressed and purified as previously described and the enzymatic 
activity was assayed by monitoring the production of NADH at sub-saturating NAD+ (3 × 
Km) and saturating IMP concentrations and 20–50 nM enzyme.9 The Ki,appvalues reported 
herein were determined from the average of two independent experiments, unless otherwise 
noted. We also evaluated inhibition of the host enzymes hIMPDH2 and hGMPR2.
Initially, modifications of the pyridyl of 2 were evaluated (Table 1). Pyridine N-oxide 31 
demonstrated comparable activity to the parent compound 2. Addition of a methoxy to the 
pyridyl 8b and 8c resulted in 5-fold more inhibition than 2. However, changing pyridyl to 2-
pyridone (30) reduced inhibitory activity by 3-fold. Replacing pyridyl with phenyl having 
both electron donating groups (EDG) and electron withdrawing groups (EWG) was 
evaluated. Compounds 8d (4-OMe), 8e (4-OCF3) and 8f (4-CN) resulted in 7-fold increase 
in inhibitory activity compared to 2. Fluorine (8g) and ester (8h) substituents were also 
tolerated. Replacing the pyridyl with a 4-hydroxy phenyl (8i) resulted in a 2-fold increase in 
inhibitory activity, whereas the 3-hydroxy (8j) and 2-hydroxy (8k) derivatives showed 
slightly decreased potency. Given the improved activityof 8d, the effect of other ethers was 
examined. For example, 18a and propargyl ester 20 shows a ~12-fold increase in activity 
compared to 2, while the corresponding carboxylic acid (19a) and tetrazole (27) were 
moderately less potent. Translocating the alkoxy from the para to meta position resulted in a 
4-fold loss in activity (18b and 19b). Compounds containing hydrophilic substituents at the 
4-position, such as hydroxamic acid 21, carboxylic acid 22 and aminomethyl 29, were found 
to be much less active. Replacing the carboxylate with hydrazide 23, 1,3,4-oxadiazolone 24, 
hydroxamidine 25, 1,2,3-oxadiazolone 26 and primary amide 28 showed 2 to 7-fold increase 
in activity.
Previous work on the benzoxazole series had established that substitution at the 2- and 3-
positions of aryl ether were important for inhibition of both Cryptosporidium parvum 
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IMPDH and MtbIMPDH2ΔCBS.39,9 Several 2,3-dichlorophenyl compounds (2, 8c, 8d, 8f, 
8g and 8i) were compared to the corresponding 2,3-difluorophenyl analogues (8l, 8o, 8m, 
8p, 8p and 8n). Three of these compounds (8l, 8p and 8q) displayed similar activity whereas 
the others were 2 to 4-fold less active. Adding another substitution on the 4-position (8r) 
resulted in slightly reduced activity. Replacement of the 2-chlorophenyl with a 2-
cyanophenyl (8s and 8t) was well tolerated. In addition, compounds with 2-cyano (8u), 2-
aminomethyl (32), and 2-hydroxy (33), and 2- benzyloxy (8v) substituents on the phenyl 
ether demonstrated MtbIMPDH2ΔCBS Ki,app values < 45 nM. However, the benzoxaborole 
(37) was not as well tolerated.
Several other areas of the Q-series were examined (Table 3). For example, the amide was 
replaced with a thioamide (9), which demonstrated a modest loss of activity. This decrease 
in potency is likely due a loss of a hydrogen bond to water, while retaining the ionic-dipole 
interaction between the thioamide NH and the carboxylate of Glu458. Furthermore, 
replacement of the amide with an amine (11) was not tolerated. In addition, activity was 
significantly decreased when the benzoxazole was replaced with an imidazo[1,2-a]pyridine 
(13). Adding a methylene between the phenyl and benzoxazole (15) also reduced activity by 
a factor of 6 compared to 8d. However, replacing the aryl ether with aniline (17a and 17b) 
resulted in increased inhibitory activity.
Selectivity of inhibition.
The cofactor binding sites are widely diverged in bacterial and eukaryotic IMPDHs, and the 
MtbIMPDH2 inhibitors exploit this divergence 9, 17. Only four compounds, 8f, 8p, 17a and 
24, modestly inhibited human IMPDH2, and in these cases selectivity ranged from a factor 
of 200 to 1000. No inhibition of human IMPDH2 was observed for the other compounds 
(maximum concentration tested was 5 μM). GMP reductase (GMPR) is closely related to 
IMPDH, and catalyzes a similar reaction, the reduction of GMP by NADPH to produce IMP, 
NADP+ and ammonia 48. The adenosine site of human GMPR2 contains the Ala-Tyr motif 
that characterizes the inhibitor binding site of MtbIMPDH2. However, none of the 
compounds inhibited human GMPR2 (maximum concentration tested was 5 μM). These 
experiments demonstrate that compounds selectively inhibit bacterial IMPDHs and do not 
affect related host enzymes.
Evaluation of antibacterial activity.
Antibacterial activity was determined for MtbIMPDH2ΔCBS inhibitors with Ki,app ≤ 40 nM 
and selected additional compounds by monitoring the growth of Mtb H37Rv (ATCC 27294) 
after one week (Table 4). Since in vitro antibiotic efficacy can vary unpredictably with 
growth conditions,49 antibacterial activity was assessed in both GAST/Fe and 7H9/ADC/
Tween media, both of which lack purines (e.g. –Gua). Two compounds, 18a and 20, 
displayed MICs less than 1 μM in both media. An additional 8 compounds, 8f, 8l, 8m, 8p, 
8u, 17a, 17b and 18b, displayed MIC ≤ 5 μM in both media. Six of these compounds 
retained antibacterial activity over two weeks: 8l, 8u, 17a, 17b, 18a and 20. Two compounds 
(21 and 22) were active in GAST/Fe medium (MIC ≤ 5 μM) but considerably less effective 
in 7H9/ADC/Tween medium. These compounds also retained activity over two weeks.
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Figure 3 shows the dependence of antibacterial activity on inhibition of MtbIMPDH2ΔCBS 
for the Q compounds described above as well as those reported previously 9. Uptake and 
metabolism also play important roles in antibacterial efficacy, so it is not surprising that 
some potent MtbIMPDH2ΔCBS inhibitors fail to display antibacterial activity. Nonetheless, 
more potent enzyme inhibition is generally associated with greater antibacterial activity, as 
expected if antibacterial activity derived from inhibition of MtbIMPDH2.
Many bacteria have the ability to salvage guanine or guanosine, and thus overcome 
inhibition of IMPDH. Mtb can salvage guanine, but not guanosine, and previously reported 
IMPDH inhibitors were much less effective in the presence of high guanine concentrations 
9–11
. For example, the MIC values of indazole sulfonamide inhibitors of MtbIMPDH2 
increased more than 25-fold in 100–125 μM guanine 10, 11. Smaller increases were observed 
for previously reported Q compounds 9. However, the MIC of only one of the new Q 
compounds, 8n, increased substantially in the presence of guanine in both media. 
Intriguingly, this compound was one of the weaker inhibitors of MtbIMPDH2 (Kiapp = 121 
nM). The MIC of one additional compound, 8c (Ki,app = 20 nM), increased in the presence 
of guanine in 7H9/ADC/Tween medium but not in GAST/Fe. The failure of guanine to 
decrease the antibacterial activity of most Q compounds would usually suggest that 
antibacterial activity derives from the engagement of another target. Alternatively, guanine 
salvage may not be sufficient to support growth in the presence of potent MtbIMPDH2 
inhibition. It is also possible that the Q inhibitors stabilize/disrupt a protein complex, 
thereby perturbing a moonlighting activity of MtbIMPDH2 in addition to enzyme activity.
We performed two experiments to further address the question of whether antibacterial 
activity derived from on-target inhibition of MtbIMPDH2. First, we evaluated the effect of 
MtbIMPDH2 depletion on the antibacterial activity of four MtbIMPDH2 inhibitors, 
including one compound with guanine-dependent antibacterial activity (1)9, and three 
compounds with guanine-independent antibacterial activity (17b, 18a and 22; note that 22 is 
only active in GAST/Fe). The downregulation of MtbIMPDH2 was achieved using strain 
guaB2 cKD, in which guaB2 expression is suppressed by anhydrotetracycline (ATc).11 The 
antibacterial activities of 1, 17b, 18a, and 22 against the wild-type strain were not affected 
by the addition of ATc (Table 5). In contrast, treatment with ATc hypersensitized the guaB2 
cKD strain to all four compounds (Figure 4), suggesting that antibacterial activity derives 
primarily from the inhibition of MtbIMPDH2.
The antibacterial activity of 1, 17b, 18a, and 22 was also assessed against Mtb strain 
SRMV2.6. This strain expresses the mutant MtbIMPDH2/Y487C, which is resistant to an 
isoquinoline sulfonamide inhibitor 11. As noted above, Tyr487 interacts with the 
benzoxazole group, so the substitution of Cys is expected to disrupt the binding of all the Q 
inhibitors. SRMV2.6 was resistant to 1 and 17b (Table 5), further confirming that the 
antibacterial activity of these compounds resulted from on-target inhibition of MtbIMPDH2. 
Interestingly, however, SRMV2.6 remained sensitive to 18a and 22.
We measured the inhibition of recombinant MtbIMPDH2/Y487C to determine if the Y487C 
mutation decreased the affinity of all the Q compounds as expected (Table 5). The values of 
Ki,app for 1 and 17b were increased by more than 300-fold and 60-fold, respectively, which 
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can account for the resistance of strain SRMV2.6. These observations further confirm that 
the antibacterial activity of 1 and 17b derive from inhibition of MtbIMPDH2. The values of 
Ki,app for 18a and 22 were similarly increased in MtbIMPDH2/Y487C, by at least 2000-fold 
and approximately 40-fold, respectively. These observations suggest that strain SRMV2.6 
should also be resistant to 1 and 18a, yet it remained sensitive to these compounds. Perhaps 
1 and 18a are concentrated or metabolized in the bacteria, or perhaps these compounds 
interfere with a moonlighting function. Alternatively, these compounds may engage an 
additional target(s). Irrespective of the ambiguous mechanism of action of 1 and 18a, 17b 
demonstrates that on-target inhibition of MtbIMPDH2 can be impervious to guanine rescue, 
suggesting that it is a vulnerable target.
Evaluation of Human Cytotoxicity Activity.
Compounds displaying potent antibacterial activity (8l, 8p, 8u, 17b, 18a and 20) were 
evaluated for cytotoxicity against HepG2 cells using a LDH release assay. Only compounds 
8p, 8u and 17b displayed measurable cytotoxicity (9–13% lactate dehydrogenase release) at 
25 μM (LD50 > 25 μM, Figure 5). Since 18a and 20 are esters of 19a, we also examined the 
cytotoxicity of this compound, and again no cytotoxicity was observed. The cytotoxicity of 
17b (25 μM) was also less than 10% in Hela, HEK293T and MCF7 cells. These experiments 
demonstrate that all of the compounds display a greater than 10-fold selectivity for 
antibacterial activity versus cytotoxicity (the recommended criteria for Mtb 50), with the 
selectivity of some exceeding 100-fold.
Preliminary pharmacokinetic evaluation of 17b.
The above observations prompted us to consider evaluating the pharmacokinetics of 17b and 
18a as a prelude to possible testing in a mouse model of tuberculosis. We first evaluated the 
stability of 17b and 18a in mouse liver microsomes. 18a was rapidly metabolized (t1/2 = 1.3 
min) in an NADPH-independent process. Compound 19a, the ester of 18a was also 
metabolized in an NADPH-independent process, although with a much longer half-life (t1/2 
= 23 min). These observations suggest that both the ester and amide bonds of 18a may be 
liabilities. Compound 17b was metabolized in an NADPH-dependent process with t1/2 = 26 
min. No decomposition of 17b was observed when it was incubated in mouse plasma at 
37 °C for 2 h. Based on these results 17b was selected for further analysis. This compound 
displayed promising pharmacokinetics in mice, with a single 20 mg/kg oral dose [formulated 
using Tween 80 (1%) and 0.5% (w/v) methylcellulose in water (99%)] producing a 
maximum plasma concentration level comparable to MIC (Cmax = 3 μM) in 0.5 h (Tmax) 
with a plasma elimination half-life of 5 h. However, 17b also displays high serum protein 
binding (>99%), which suggests that the free drug concentration is insufficient to achieve in 
vivo efficacy. Further optimization of 17b to increase antibacterial activity and decrease 
plasma protein binding is ongoing.
CONCLUSIONS
The SAR of the benzoxazole-based IMPDH inhibitors (Q-series) has been expanded by 
replacing the 4-pyridyl with phenyl or benzyl groups containing a variety of hydrogen 
bonding and ionic-dipole interacting substituents. Modifications to the central amide and 
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benoxazole also reinforced the importance of interactions between the inhibitors and 
Glu458, and the spatial orientation provided by the central heterocycle, respectively. Two 
MtbIMPDH2 inhibitors displayed antibacterial activity with MIC values ≤ 1 μM, and 
another eight compounds displayed MICs ≤ 5 μM. The antibacterial activity of the best 
candidate, 17b, derives from inhibition of MtbIMPDH2, yet is not affected by the presence 
of guanine. This observation alleviates the concern that guanine salvage can rescue bacteria 
from MtbIMPDH2 inhibition. We note that previously reported MtbIMPDH2 inhibitors were 
not as potent as the current compounds, and suggest that the ability of guanine to protect 
bacteria derived from incomplete inhibition of MtbIMDPH2. The values of Ki,app for the 
best inhibitors are 25-fold more potent than the indazole sulfonamide inhibitor that called 
into question the vulnerability of MtbIMPDH2,10 suggesting that guanine salvage cannot 
overcome potent inhibition. 17b was also non-toxic at 25 μM in four human cell lines. 
Overall, this study provides further evidence for the vulnerability of MtbIMPDH2.
Experimental Section
Synthetic Chemistry.—Unless otherwise noted, all reagents and solvents were purchased 
from commercial sources and used without further purification. All reactions were 
performed under a nitrogen atmosphere in dried glassware unless otherwise noted. All NMR 
spectra were obtained using a 400 MHz spectrometer. For 1H NMR, all chemical shifts are 
reported in δ units ppm and are referenced to tetramethylsilane (TMS). All chemical shift 
values are also reported with multiplicity, coupling constants, and proton count. Coupling 
constants (J) are reported in hertz. Column chromatography was carried out on SILICYCLE 
SiliaFlash silica gel F60 (40−63 μm, mesh 230−400). High-resolution mass spectra were 
obtained using a Q-tof UE521 mass spectrometer (University of Illinois, SCS, and Mass 
Spectrometry Laboratory). HPLC conditions: All final compounds have a chemical purity of 
>98% as determined by analysis using a Varian Prostar (380-LC) HPLC instrument 
equipped with a quaternary pump and a Varian Microsorb MV-100–5 C-8 column (250 mm 
× 4.6 mm). UV absorption was monitored at 332 nm. All samples were dissolved in THF 
(1–2 mg/mL) and the injection volume was 20 μL. HPLC gradient was 30% acetonitrile and 
70% water (both solvents contain 0.05% formic acid) with a total run time of 20 min and a 
flow rate of 1.0 mL/min.
General Procedure for the Synthesis of 5-nitro-2-phenylbenzo[d]oxazoles 
(4): To a stirred solution of 2-amino-4-nitrophenol (1 mmol) and aromatic aldehydes (1 
mmol) in anhydrous xylene DarcoKB (300 mg) was added. The solution was stirred under 
O2 atmosphere at 140 ºC for 6–8 h. After completion of the reaction as observed from TLC, 
reaction mixture was filtered with the aid of Celite, which was washed with hot ethyl acetate 
(3×20 mL). The filtrate was concentrated, and the products were either used directly or 
recrystallized using ethyl acetate and hexane.
General Procedure for the Synthesis of 5: 5-Nitro-2-arylbenzo[d]oxazole 4 (1 mmol) 
was dissolved in 10 mL EtOAc:MeOH (1:1) and 10% Pd/C (catalytic) was added and stirred 
well under a H2 atmosphere for 3 h. After the successful completion, the reaction mixture 
was filtered through celite and the filtrate was concentrated under reduced pressure. The 
crude amines were used directly or recrystallized using ethyl acetate and hexane.
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General Procedure for the Synthesis of Phenyl Ethers 6: Substituted phenol (1 
mmol) was added to the solution of methyl (+)-methyl D-lactate (1.38 mmol) in anhydrous 
THF (6 mL) under a nitrogen atmosphere. The solution was cooled to 0 °C, followed by 
PPh3 (1.20 mmol) was added portion wise to the stirred solution. DEAD (1.50 mmol) was 
added dropwise to the above solution and stirred well at room temperature for 4 h. After 
completion, solvent was removed under reduced pressure and the crude residue was purified 
by column chromatography on silica gel using ethyl acetate/n-hexane (10:90) to yield 
corresponding phenyl ether as a colorless liquid (85–90% Yield).
General Procedure for Ester Hydrolysis for Preparation of 7: LiOH (1.5 mmol) 
was added portion wise to the stirred solution of ester 6 (1 mmol) in 5 mL THF:MeOH (2:3) 
at 0 ºC. The reaction was brought to room temperature and stirred well for 4 h. The solvents 
were removed under reduced pressure, 1N HCl was added to a pH of 4 and then the mixture 
was extracted with ethyl acetate. The organic layer was washed with brine, dried using 
anhydrous MgSO4, filtered, and concentrated under reduced pressure. The crude acids were 
used in the next step without purification.
(S)-2-(2,3-Dichlorophenoxy)-N-(2-(pyridin-4-yl)benzo[d]oxazol-5-
yl)propanamide (8a): Prepared and characterized previously.39
General Procedure for Synthesis of 8b-8v: EDC·HCl (1.5 mmol) was added to the 
stirred solution of acid 7 (1 mmol) and amine 5 (1 mmol) in dry DMF at 0 ºC under nitrogen 
atmosphere. The reaction mixture was stirred overnight at room temperature. After 
completion of the reaction, excess water was added and extracted with ethyl acetate. The 
organic layer was washed with brine and dried using anhydrous MgSO4. The solvent was 
removed under reduced pressure and the crude residue was purified through column 
chromatography using ethyl acetate/n-hexane.
(S)-2-(2,3-Dichlorophenoxy)-N-(2-(2-methoxypyridin-4-yl)benzo[d]oxazol-5-
yl)propanamide (8b): White solid (306 mg, 66%), 1H NMR (DMSO-d6) 10.34 (s, 1H, 
NH), 8.93 (d, J = 2.00 Hz, 1H, CH), 8.39–8.36 (m, 1H, CH), 8.06 (d, J = 2.00 Hz, 1H, CH), 
7.69 (d, J = 8.80 Hz, 1H, CH), 7.52 (dd, J = 8.90 Hz, J = 2.00 Hz, 1H, CH), 7.30–7.26 (m, 
1H, CH), 7.22 (t, J = 1.20 Hz, 1H, CH), 7.02–7.00 (m, 2H, 2×CH), 4.98 (q, J = 6.80 Hz, 1H, 
CH), 3.92 (s, 3H, -OCH3), 1.59 (d, J = 6.80 Hz, 3H, CH3). Purity 98% (tR = 15.13). m.p. 
165–166 C.
(S)-2-(2,3-dichlorophenoxy)-N-(2-(6-methoxypyridin-3-yl)benzo[d]oxazol-5-
yl)propanamide (8c): White solid (315 mg, 69%), 1H NMR (DMSO-d6) 10.34 (s, 1H, 
NH), 8.92 (m, 1H, CH), 8.39–8.37 (m, 1H, CH), 8.06–8.05 (m, 1H, CH), 7.69–7.67 (m, 1H, 
CH), 7.53– 7.51 (m, 1H, CH), 7.27–7.20 (m, 2H, 2×CH), 7.01–6.98 (m, 2H, 2×CH), 5.01 (q, 
J = 6.80 Hz, 1H, CH), 3.91 (s, 3H, -OCH3), 1.58 (d, J = 6.80 Hz, 3H, CH3). Purity 97% (tR 
= 14.85). m.p. 156–157 C.
(S)-2-(2,3-Dichlorophenoxy)-N-(2-(4-methoxyphenyl)benzo[d]oxazol-5-
yl)propanamide (8d): White solid (351 mg, 77%), 1H NMR (DMSO-d6) 10.32 (s, 1H, 
NH), 8.08 (d, J = 8.80 Hz, 2H, 2×CH), 8.03 (d, J = 2.00 Hz, 1H, CH), 7.65 (d, J = 8.80 Hz, 
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1H, CH), 7.50–7.48 (m, 1H, CH), 7.27 (t, J = 8.20 Hz, 1H, CH), 7.21–7.19 (m, 1H, CH), 
7.10 (d, J = 8.80 Hz, 2H, 2×CH), 7.01–6.99 (m, 1H, CH), 4.98 (q, J = 6.80 Hz, 1H, CH), 
3.82 (s, 3H, -OCH3), 1.59 (d, J = 6.80 Hz, 3H, CH3). Purity 99% (tR = 15.30). m.p. 230 C.
(S)-2-(2,3-Dichlorophenoxy)-N-(2-(4-
(trifluoromethoxy)phenyl)benzo[d]oxazol-5-yl)propanamide (8e): White solid 
(357 mg, 70%), 1H NMR (DMSO-d6) 10.41 (s, 1H, NH), 8.31 (d, J = 8.80 Hz, 2H, 2×CH), 
8.16 (m, 1H, CH), 7.77 (d, J = 9.00 Hz, 1H, CH), 7.61 (d, J = 8.00 Hz, 2H, 2×CH), 7.59 (m, 
1H), 7.32 (t, J = 8.20 Hz, 1H, CH), 7.26–7.24 (m, 1H, CH), 7.05 (d, J = 6.40 Hz, 1H, CH), 
5.03 (q, J = 6.20 Hz, 1H, CH), 1.64 (d, J = 6.40 Hz, 3H, CH3). Purity 99% (tR = 17.15). m.p. 
140–141 C.
(S)-N-(2-(4-Cyanophenyl)benzo[d]oxazol-5-yl)-2-(2,3-
dichlorophenoxy)propanamide (8f): Yellow solid (311 mg, 69%), 1H NMR (DMSO-
d6) 10.38 (s, 1H, NH), 8.28 (dd, J = 8.20 Hz, J = 1.20, 2H, 2×CH), 8.14 (m, 1H, CH), 8.02 
(dd, J = 8.20 Hz, J = 1.20 Hz, 2H, 2×CH), 7.75–7.73 (m, 1H, CH), 7.58–7.56 (m, 1H, CH), 
7.26 (t, J = 1.60 Hz, 1H, CH), 7.20 (m, 1H, CH), 7.00 (d, J = 8.40 Hz m, 1H, CH), 5.01 (q, 
1H, J = 6.80 Hz, CH), 1.58 (d, 3H, J = 6.80 Hz, CH3). Purity 99% (tR = 14.85). m.p. 183–
184 C.
(S)-2-(2,3-Dichlorophenoxy)-N-(2-(4-fluorophenyl)benzo[d]oxazol-5-
yl)propanamide (8g): White solid (351 mg, 79%), 1H NMR (DMSO-d6) 10.42 (s, 1H, 
NH), 8.26–8.23 (m, 2H, 2×CH), 8.13 (m, 1H, CH), 7.76–7.74 (m, 1H, CH), 7.59–7.44 (m, 
3H, 3×CH), 7.32–7.26 (m, 2H, 2×CH), 7.06–7.04 (m, 1H, CH), 5.04 (q, J = 6.00 Hz, 1H, 
CH), 1.64 (d, J = 6.00 Hz, 3H, CH3). Purity 98% (tR = 15.73). m.p. 213–214 C.
Methyl (S)-4-(5-(2-(2,3-dichlorophenoxy)propanamido)benzo[d]oxazol-2-
yl)benzoate (8h): White solid (329 mg, 68%), 1H NMR (DMSO-d6) 10.37 (s, 1H, NH), 
8.29–8.26 (m, 1H, CH), 8.11 (d, J = 8.80 Hz, 2H, 2×CH), 7.86 (m, 1H, CH), 7.73 (dd, J = 
8.80 Hz, J = 3.20 Hz, 1H, CH), 7.56 (d, J = 8.20 Hz, 1H, CH), 7.40 (m, 1H, CH), 7.27–7.20 
(m, 2H, 2×CH), 7.00 (dd, J = 8.80 Hz, J = 2.00 Hz, 1H, CH), 5.02 ( q, 1H, J = 6.80 Hz,, 1H, 
CH), 3.85 (s, 3H, -COOCH3), 1.59 (d, 3H, J = 6.00 Hz, CH3). Purity 99% (tR = 15.60). m.p. 
197–198 C.
(S)-2-(2,3-Dichlorophenoxy)-N-(2-(4-hydroxyphenyl)benzo[d]oxazol-5-
yl)propanamide (8i): White solid (313 mg, 71%), 1H NMR (DMSO-d6) 10.30 (s, 1H, 
NH), 8.00–7.99 (m, 1H, CH), 7.97 (d, J = 8.40 Hz, 2H, 2×CH), 7.62 (d, J = 8.80 Hz, 1H, 
CH), 7.48–7.46 (m, 1H, CH), 7.27 (t, J = 8.00 Hz, 1H, CH), 7.00 (d, J = 8.40 Hz, 1H, CH), 
6.91 (d, J = 8.80 Hz, 2H, 2×CH), 4.47 (q, J = 6.40 Hz, 1H, CH), 1.58 (d, J = 6.80 Hz, 3H, 
CH3). Purity 99% (tR = 13.11). m.p. 213.5–214.5 C.
(S)-2-(2,3-Dichlorophenoxy)-N-(2-(3-hydroxyphenyl)benzo[d]oxazol-5-
yl)propanamide (8j): White solid (300 mg, 68%), 1H NMR (DMSO-d6) 10.38 (s, 1H, 
NH), 9.75 (s, 1H, OH), 8.12 (s, 1H, CH), 7.74 (d, J = 9.20Hz, 1H, CH), 7.61–7.55 (m, 3H, 
3×CH), 7.40 (t, J = 8.00 Hz, 1H, CH), 7.32 (t, J = 8.20 Hz, 1H, CH), 7.26 (m, 1H), 7.06–
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7.01 (m, 2H, 2×CH), 5.03 (q, J = 6.80 Hz, 1H, CH), 1.64 (d, J = 6.40 Hz, 3H, CH3). Purity 
98% (tR = 13.36). m.p. 259 C.
(S)-2-(2,3-Dichlorophenoxy)-N-(2-(2-hydroxyphenyl)benzo[d]oxazol-5-
yl)propanamide (8k): White solid (287 mg, 65%), 1H NMR (DMSO-d6) 11.10 (s, 1H, 
OH), 10.41 (s, 1H, NH), 8.13 (d, J = 2.00 Hz, 1H, CH), 7.97 (dd, J = 7.60 Hz, J = 1.20 Hz, 
1H, CH), 7.76 (d, J = 8.40 Hz, 1H, CH), 7.55 (dd, J = 8.40 Hz, J = 2.00 Hz, 1H, CH), 7.54–
7.48 (m, 1H, CH), 7.26 (t, J = 8.00 Hz, 1H, CH), 7.19 (m, 1H, CH), 7.09–7.00 (m, 3H, 
3×CH), 5.00 (q, J = 6.80 Hz, 1H, CH), 1.59 (d, J = 6.60 Hz, 3H, CH3). Purity 99% (tR = 
16.99). m.p. 209–210 C.
(S)-2-(2,3-Difluorophenoxy)-N-(2-(pyridin-4-yl)benzo[d]oxazol-5-
yl)propanamide (8l): White solid (268 mg, 68%), 1H NMR (DMSO-d6) 10.40 (s, 1H, 
NH), 8.79 (dd, J = 4.20 Hz, J = 1.20 Hz, 2H, CH), 8.16 (m, 1H, CH), 8.04 (t, J = 2.00 Hz, 
2H, 2×CH), 7.77 (d, J = 8.80 Hz, 1H, CH), 7.62 (m, 1H, CH), 7.62–7.60 (m, 1H, CH), 4.96 
(q, J = 6.80 Hz, 1H, CH), 1.58 (d, J = 6.80 Hz, 3H, CH3). Purity 99% (tR = 14.45). m.p. 
189–190 C.
(S)-2-(2,3-Difluorophenoxy)-N-(2-(4-methoxyphenyl)benzo[d]oxazol-5-
yl)propanamide (8m): White solid (322 mg, 76%), 1H NMR (DMSO-d6) 10.32 (s, 1H, 
NH), 8.08 (d, J = 9.20 Hz, 2H, 2×CH), 8.02 (d, J = 1.60 Hz, 1H, CH), 7.64 (d, J = 8.40 Hz, 
1H, CH), 7.50 (d, J = 6.80 Hz, 1H, CH), 7.10 (d, J = 8.80 Hz, 3H, 3×CH), 6.99 (m, 1H, CH), 
6.89 (t, J = 2.00 Hz, 1H, CH), 4.95 (q, J = 6.80 Hz, 1H, CH), 1.57 (d, J = 6.40 Hz, 3H, CH3). 
Purity 97% (tR = 13.95). m.p. 179–180 C.
(S)-2-(2,3-Difluorophenoxy)-N-(2-(4-hydroxyphenyl)benzo[d]oxazol-5-
yl)propanamide (8n): White solid (291 mg, 71%), 1H NMR (DMSO-d6) 10.36 (s, 1H, 
OH), 10.33 (s, 1H, NH), 8.04 (d, J = 2.00 Hz, 2H, 2×CH), 8.01 (m, 1H, CH), 7.67 (d, J = 
8.80 Hz, 1H, CH), 7.52 (d, J = 8.20 Hz,, 1H, CH), 7.15–6.97 (m, 3H, 3×CH), 6.96 (d, J = 
8.40 Hz, 2H, 2×CH), 4.99 (q, 1H, J = 6.80 Hz, CH), 1.62 (d, 3H, J = 6.40 Hz, CH3). Purity 
98% (tR = 11.36). m.p. 182–183 C.
(S)-2-(2,3-Difluorophenoxy)-N-(2-(6-methoxypyridin-3-yl)benzo[d]oxazol-5-
yl)propanamide (8o): White solid (311 mg, 69%), 1H NMR (DMSO-d6) 10.49 (s, 1H, 
NH), 8.97 (s,, 1H, CH), 8.40 (dd, J = 8.40 Hz, J = 2.00 Hz, 1H, CH), 8.11 (m, 1H, CH), 7.73 
(d, J = 8.00 Hz, 1H, CH), 7.59–7.56 (m, 1H, CH), 7.19–6.98 (m, 3H, 3×CH), 6.94 (t, J = 
2.40 Hz, 1H, CH), 5.00 (q, J = 6.40 Hz, 1H, CH), 3.17 (s, 3H, -OCH3), 1.63 (d, J = 6.40 Hz, 
3H, CH3). Purity 99% (tR = 13.25). m.p. 177–178 C.
(S)-N-(2-(4-Cyanophenyl)benzo[d]oxazol-5-yl)-2-(2,3-
difluorophenoxy)propanamide (8p): White solid (289 mg, 69%), 1H NMR (DMSO-
d6) 10.44 (s, 1H, NH), 8.34 (d, J = 8.40 Hz, 2H, 2×CH), 8.19 (d, J = 1.60 Hz, 1H, CH), 8.07 
(d, J = 8.8 Hz, 2H, 2×CH), 7.79 (d, J = 8.80 Hz, 1H, CH), 7.65–7.62 (m, 1H, CH), 7.17–7.12 
(m, 1H, CH), 7.06–7.02 (m, 1H, CH), 6.95 (t, J = 2.00 Hz, 1H, CH), 5.01 (q,, J = 6.40 Hz, 
1H, CH), 1.63 (d, J = 6.8 Hz, 3H, CH3). Purity 98% (tR = 13.24). m.p. 176–177 C.
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(S)-2-(2,3-Difluorophenoxy)-N-(2-(4-fluorophenyl)benzo[d]oxazol-5-
yl)propanamide (8q): White solid (317 mg, 77%), 1H NMR (DMSO-d6) 10.40 (s, 1H, 
NH), 8.24 (dd, J = 8.60 Hz, J = 5.40 Hz, 2H, 2×CH), 8.13 (d, J = 1.60 Hz,1H, CH), 7.74 (d, 
J = 9.20 Hz,, 1H, CH), 7.58 (dd, J = 8.80 Hz, J = 2.00 Hz, 1H, CH), 7.46 (td, J = 8.80, J = 
1.00 Hz, 2H, 2×CH), 7.17–7.12 (m, 1H, CH), 7.06–7.02 (m, 1H, CH), 6.96–6.92 (m, 1H, 
CH), 5.00 (q, J = 6.40 Hz, 1H, CH), 1.63 (d, J = 6.80 Hz, 3H, CH3). Purity 97% (tR = 
14.29). m.p. 194–195 C.
(S)-N-(2-(4-Cyanophenyl)benzo[d]oxazol-5-yl)-2-(2,3,4-
trifluorophenoxy)propanamide (8r): White solid (270 mg, 62%), 1H NMR (DMSO-d6) 
10.42 (s, 1H, NH), 8.34 (d, J = 6.80 Hz, 2H, 2×CH), 8.19 (s, 1H, CH), 8.08 (d, J = 7.20 Hz, 
2H, 2×CH), 7.80 (d, J = 8.00 Hz, 1H, CH), 7.63 (d, J = 8.40 Hz, 1H, CH), 7.27 (d, J = 10.00 
Hz 1H, CH), 6.98 (m, 1H, CH), 4.98 (q, J = 6.40 Hz, 1H, CH), 1.61 (d, J = 6.80 Hz, 3H, 
CH3). Purity 99% (tR = 13.60). m.p. 184–185 C.
(S)-2-(2-Cyanophenoxy)-N-(2-(pyridin-4-yl)benzo[d]oxazol-5-yl)propanamide 
(8s): White solid (261 mg, 68%), 1H NMR (DMSO-d6) 10.49 (s, 1H, NH), 8.84 (dd, J = 
4.00 Hz, J = 1.60 Hz, 2H, 2×CH), 8.21 (d, J = 2.00 Hz, 1H, CH), 8.09 (dd, J = 4.40 Hz, J = 
1.60 Hz, 2H, 2×CH), 7.83–7.77 (m, 2H, 2×CH), 7.68–7.63 (m, 2H, 2×CH), 7.14–7.11 (m, 
2H, 2×CH), 5.11 (q, J = 6.80 Hz, 1H, CH), 1.66 ( d, J = 6.80 Hz, 3H, CH3). Purity 98% (tR = 
12.67). m.p. 229–230 C.
(S)-2-(2-Cyano-3-fluorophenoxy)-N-(2-(pyridin-4-yl)benzo[d]oxazol-5-
yl)propanamide (8t): White solid (285 mg, 71%), 1H NMR (DMSO-d6) 10.51 (s, 1H, 
NH), 8.84 (dd, J = 6.00 Hz, J = 1.00 Hz, 2H, 2×CH), 8.20 (s, 1H, CH), 8.09 (dd, J = 6.00 
Hz, J = 1.00 Hz, 2H, 2×CH), 7.84–7.81 (m, 1H, CH), 7.73–7.63 (m, 2H, 2×CH), 7.10 (t, J = 
8.80 Hz, 1H, CH), 6.99–6.97 (d, J = 8.80 Hz, 1H, CH), 5.16 (q, J = 6.40 Hz, 1H, CH), 1.67 
(d, J = 6.80 Hz, 3H, CH3). Purity 98% (tR = 13.44). m.p. 189-dec C.
(S)-2-(2-Cyanophenoxy)-N-(2-(4-methoxyphenyl)benzo[d]oxazol-5-
yl)propanamide (8u): White solid (318 mg, 77%), 1H NMR (DMSO-d6) 10.41 (s, 1H, 
NH), 8.13 (d, J = 8.80 Hz, 2H, 2×CH), 8.07 (m, 1H, CH), 7.78 (d, J = 8.80 Hz, 1H, CH), 
7.72 (m, 2H, 3×CH), 7.54 (d, J = 8.00 Hz, 1H, CH), 7.21–7.04 (m, 4H, 4×CH), 5.09 (q, J = 
6.00 Hz, 1H, CH), 3.82 (s, 3H, OCH3), 1.65 (d, J = 6.40 Hz, 3H, CH3). Purity 99% (tR = 
12.99). m.p. 162–163 C.
(S)-2-(2-(Benzyloxy)phenoxy)-N-(2-(4-cyanophenyl)benzo[d]oxazol-5-
yl)propanamide (8v): White solid (337 mg, 69%), 1H NMR (DMSO-d6) 10.23 (s, 1H, 
NH), 8.34 (d, J = 8.00 Hz, 2H, 2×CH), 8.21 (m, 1H, CH), 8.08 (d, J = 8.00 Hz, 2H, 2×CH), 
7.76 (d, J = 8.80 Hz, 1H, CH), 7.61–7.58 (m, 1H, CH), 7.50 (d, J = 7.60 Hz, 2H, 2×CH), 
7.38–7.29 (m, 3H, 3×CH), 7.08 (m, 2H, 2×CH), 6.93(m, 2H, 2×CH), 5.17 (s, 2H, -OCH2-), 
4.82 (q, J = 6.40 Hz, 1H, CH), 1.57 (d, J = 6.80 Hz, 3H, CH3). Purity 99% (tR = 15.31). m.p. 
144–145 C.
(S)-2-(2,3-Dichlorophenoxy)-N-(2-(4-methoxyphenyl)benzo[d]oxazol-5-
yl)propanethioamide (9): A mixture of amide 8 (Ar = 4-OMePh, R = 2,3-diCl, 1 mmol) 
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and Lawesson’s reagent (1 mmol) was dissolved in dry dioxane (5 mL) and refluxed well for 
2h. After cooling to room temperature, dioxane was removed under reduced pressure and the 
crude product was purified through column chromatography. White solid (335 mg, 71%), 1H 
NMR (DMSO-d6) 11.72 (s, 1H, NH), 8.10–8.08 (m, 3H, 3×CH), 7.76–7.70 (m, 1H, CH), 
7.51–7.50 (m, 1H, CH), 7.32–7.29 (m, 1H, CH), 7.22–7.20 (m, 1H, CH), 7.14–7.02 (m, 2H, 
2×CH), 7.02–7.00 (m, 1H, CH), 5.20 (q, J = 6.80 Hz, 1H, CH), 1.70 (d, J = 6.80 Hz, 3H, 
CH3). Purity 98% (tR = 17.09). m.p. 132–139 C.
(S)-2-(2,3-Dichlorophenoxy)propanal (10): DIBAL-H (1.0 M, in cyclohexane, 2 
mmol) was added dropwise to the stirred solution of ester 6a (1 mmol) in dry CH2Cl2 (4 
mL) under a nitrogen atmosphere at −78 ºC. After completion of the addition, stirring was 
continued at the same temperature for 1 h. Aq. HCl (1 N, 3 mL) was added carefully. The 
bath was removed and the mixture was extracted with Et2O (3 ×30 mL). The combined 
organic layers were washed with water (10 mL) and brine (10 mL) and dried over anhydrous 
MgSO4. The solvent was removed under reduced pressure and the crude reaction mixture 
was purified through column chromatography. Colorless oil (193 mg, 89%), 1H NMR 
(CDCl3) 9.72 (s, 1H, CH), 7.10 (m, 2H, 2×CH), 6.74–6.71 (m, 1H, CH), 4.62–4.60 (m, 1H, 
CH), 1.51 (d, J = 7.20 Hz, 3H, CH3).
(S)-N-(2-(2,3-Dichlorophenoxy)propyl)-2-(4-methoxyphenyl)benzo[d]oxazol-5-
amine (11): Aldehyde 10 (1 mmol) was dissolved in DCE (25 mL) at 0 °C. Benzoxazole 
amine 5 (Ar = 4-OMePh, 1 mmol) and sodium triacetoxyborohydride (2 mmol) were added 
to the above solution and stirred well. The reaction mixture was stirred for 1.5 h and 
quenched with satd. NaHCO3 solution (20 mL), and the product was extracted with CH2Cl2 
(2 × 20 mL). The organic layer was washed with brine and dried using anhydrous MgSO4. 
The solvent was removed under reduced pressure and crude mixture was purified through 
column chromatography. Colorless oil (351 mg, 81%), 1H NMR (CDCl3) 8.11 (dd, J = 9.20 
Hz, J = 2.00 Hz, 2H, 2×CH), 7.29 (dd, J = 8.80 Hz, J = 2.40 Hz, 1H, CH), 7.05–7.02 (m, 2H, 
2×CH), 6.96 (dd, J = 9.00 Hz, J = 2.60 Hz, 2H, 2×CH), 6.92–6.91 (m, 1H, CH), 6.81–6.78 
(m, 1H, CH), 6.59 (dd, J = 8.60 Hz, J = 2.20 Hz, 1H, CH), 4.64 (m, 1H, CH), 4.21 (bs, 1H, 
NH), 3.84 ( s, 3H, -OCH3), 3.47–3.39 (m, 2H, -CH2-), 1.39 (d, J = 6.20 Hz, 3H, CH3). 
Purity 98% (tR = 17.11).
2-(4-Methoxyphenyl)-6-nitroimidazo[1,2-a]pyridine (12): 5-Nitropyridin-2-amine (1 
mmol) and NaHCO3 (2 mmol) was added to a stirred solution of 2-bromo-4′-
methoxyacetophenone (1 mmol) in ethanol at room temperature and the reaction mixture 
was refluxed for overnight. After completion, the solvent was removed under reduced 
pressure and the crude material was dissolved in water and extracted with ethyl acetate. The 
organic layer was washed with brine and dried using anhydrous MgSO4, filtered and 
concentrated under reduced pressure. The product was recrystallized using ethyl acetate and 
hexane. Brown solid (237 mg, 88%), 1H NMR (DMSO-d6) 9.76 (m, 1H, CH), 8.47 (s, 1H, 
CH), 7.90–7.88 (m, 3H, 3×CH), 7.67–7.65 (m, 1H, CH), 7.61 (d, 2H, J = 8.80 Hz, 2×CH, 
3.78 (s, 3H, -OCH3).
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(S)-2-(2,3-Dichlorophenoxy)-N-(2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-6-
yl)propanamide (13): To the stirred solution of 2-(4-methoxyphenyl)-6-nitroimidazo[1,2-
a]pyridine 12 (1 mmol) in ethanol and ethyl acetate, SnCl2 (2 mmol) was added and refluxed 
for 2h. Solvent was removed under reduced pressure and the reaction was quenched by 
adding a saturated solution of NaHCO3 solution and extracted with ethyl acetate. The 
organic phase was washed with brine, dried over anhydrous MgSO4, filtered and 
concentrated under reduced pressure. The crude amine was used in the next step without any 
purification. EDC·HCl (1.5 mmol) was added to the stirred solution of acid 7 (R = 2,3-diCl, 
1 mmol) and amine (1 mmol) in dry DMF at 0 ºC under a nitrogen atmosphere. The reaction 
mixture was stirred overnight at room temperature. After completion of the reaction, water 
was added and extracted with ethyl acetate. The organic layer was washed with brine and 
dried using anhydrous MgSO4. The solvent was removed under reduced pressure. The crude 
residue was purified through column chromatography to give the desired product. Brown 
solid (273 mg, 60%), 1H NMR (DMSO-d6) 10.35 (s, 1H, NH), 9.13 (s, 1H, CH), 8.33 (s, 
1H, CH), 7.84 (d, J = 8.40 Hz, 2H, 2×CH), 7.53 (d, J = 8.00 Hz, 1H, CH), 7.24–6.92 (m, 6H, 
6×CH), 5.02 (q, J = 6.40 Hz, 1H, CH), 3.79 (s, 3H, -OCH3), 1.62 (d, J = 6.40 Hz, 3H, CH3). 
Purity 97% (tR = 12.00). m.p. 146–147 C.
2-(4-Methoxybenzyl)-5-nitrobenzo[d]oxazole (14): DABCO (2 mmol) was added to 
the stirred solution of 1-(2,2-dibromovinyl)-4-methoxybenzene (1 mmol) and 2-amino-4-
nitrophenol (1 mmol) in NMP (5 mL) under nitrogen atmosphere. The solution was stirred 
well for 24 h at 100 ºC. After completion, reaction was quenched by the addition of water 
and extracted with ethyl acetate. The organic layer was washed with brine and dried using 
MgSO4, filtered and concentrated under reduced pressure. The crude product was purified 
using column chromatography. Yellow solid (171 mg, 60%), 1H NMR (CDCl3) 8.57–8.56 
(m, 1H, CH), 8.28–8.25 (m, 1H, CH), 7.57–7.55 (m, 1H, CH), 7.31–7.29 (m, 2H, 2×CH), 
6.91–6.89 (m, 2H, 2×CH), 4.66 (s, 2H, -CH2-), 3.80 (s, 3H, -OCH3).
(S)-2-(2,3-dichlorophenoxy)-N-(2-(4-methoxybenzyl)benzo[d]oxazol-5-yl)prop-
anamide (15): 5-Nitro-2-arylbenzo[d]oxazoles (1 mmol) was dissolved in 10 mL 
EtOAc:MeOH (1:1) and 10% Pd/C (catalytic) was added and stirred well under a H2 
atmosphere for 2–3 h. After the successful completion, reaction mixture was filtered through 
celite and the filtrate was concentrated under reduced pressure. The crude amine was 
recrystallized using ethyl acetate and hexane. The amine was proceeded to next step without 
any chromatographic purification. EDC·HCl (1.5 mmol) was added to the stirred solution of 
acid 7 (R = 2,3-diCl, 1 mmol), amine (1 mmol) in dry DMF at 0 ºC under nitrogen 
atmosphere. Reaction mixture was stirred well for overnight at room temperature. After 
completion of the reaction, excess water was added and extracted with ethyl acetate. The 
organic layer was washed with brine and dried using MgSO4. The solvent was removed 
under reduced pressure and crude residue was purified through column chromatography 
using ethyl acetate/n-hexane. White solid (315 mg, 67%), 1H NMR (CDCl3) 8.71 (s, 1H, 
NH), 7.97 (bs, 1H, CH), 7.46 (d, J = 8.00 Hz, 1H, CH), 7.39 (d, J = 8.20 Hz, 1H, CH), 7.28 
(d, J = 8.00 Hz, 2H, 2×CH), 7.18–7.16 (m, 2H, 2×CH), 6.91–6.86 (m, 3H, 3×CH), 4.86 (q, J 
= 6.80 Hz, 1H, CH), 4.19 (s, 2H, -CH2-), 3.78 (s, 3H, -OCH3), 1.73 (d, J = 7.20 Hz, 3H, 
CH3). Purity 97% (tR = 14.78). m.p. 143–147 C.
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Synthesis of 17: A mixture of L-alanine (163 mg, 1.82 mmol), Cs2CO3 (1.19 g, 3.65 
mmol), and CuI (69.7 mg, 0.36 mmol) was added to the stirred solution of 1,2-dichloro-3-
iodobenzene or 1,2-difluoro-3-iodobenzene (1.83 mmol) in dry DMF (3 mL) under a 
nitrogen atmosphere. The reaction mixture was heated at 90 °C for 24 h. After completion, 
the reaction mixture was allowed to cool and water was added. The pH was adjusted to 3−5 
by the addition of 2N HCl and extracted with ethyl acetate. The organic layer was washed 
with brine, dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. 
The crude acid 16 was used in the next step without further purification. Acid 16 (1 mmol) 
was added to the stirred solution of amine 5 (Ar = 4-CNPh, 1 mmol) in dry DMF at 0 ºC 
followed by HATU (1.2 mmol) and stirred well for overnight at room temperature. After 
completion, excess water was added to the reaction and extracted with ethyl acetate. The 
organic layer was washed with brine and dried over anhydrous MgSO4, filtered, and 
concentrated. The residue was purified by column chromatography using ethyl acetate/n-
hexane.
(S)-N-(2-(4-Cyanophenyl)benzo[d]oxazol-5-yl)-2-((2,3-
dichlorophenyl)amino)propanamide (17a): Light brown powder (202 mg, 45%), 1H 
NMR (DMSO-d6) 10.39 (s, 1H, NH), 8.34 (d, J = 8.00 Hz, 2H, 2×CH), 8.20 (s, 1H, CH), 
8.07 (d, J = 8.40 Hz, 2H, 2×CH), 7.81 (d, J = 8.40 Hz, 1H, CH), 7.60–7.58 (m, 1H, CH), 
7.18 (t, J = 8.20 Hz, 1H, CH), 6.88 (d, J = 7.60 Hz, 1H, CH), 6.65 (d, J = 8.40 Hz, 1H, CH), 
5.61 (d,J = 8.00 Hz, 1H, NH), 4.26 (m, 1H, CH), 1.54 (d, J = 6.8Hz, 3H, CH3). Purity 99% 
(tR = 14.95). m.p. 201–202 C.
(S)-N-(2-(4-Cyanophenyl)benzo[d]oxazol-5-yl)-2-((2,3-
difluorophenyl)amino)propanamide (17b): Yellow powder (225 mg, 54%) 1H NMR 
(DMSO-d6) 10.29 ( s, 1H, NH), 8.33 (d, J = 8.40 Hz, 2H, 2×CH), 8.20 (m, 1H, CH), 8.07 (d, 
J = 8.40 Hz, 1H, CH), 7.77 (d, J = 8.80 Hz, 1H, CH), 7.60 (d, J = 8.80 Hz, 1H, CH), 6.96 (q, 
J = 7.60 Hz, 1H, CH), 6.59 (m, 1H, CH), 6.51 (t, J = 7.60 Hz, 1H, CH), 5.92 (d,J = 7.60 Hz, 
1H, NH), 4.18 (q, J = 6.80 Hz, 1H, CH), 1.51 (d, J = 6.40 Hz, 3H, CH3). Purity 99% (tR = 
12.95). m.p. 197–198 C.
Synthesis of 18: Arylbenzoxazole 8i or 8j (1 mmol) was dissolved in dry DMF (5 mL) in 
an oven dried round bottom flask and cooled to 0 ºC. K2CO3 (2 mmol) was added to the 
cold solution and stirred well for ten minutes, then ethyl bromoacetate (1.5 mmol) was 
added and stirred well at room temperature for 6 h. After completion, the reaction was 
quenched with water and extracted with ethyl acetate (20 mL) and the organic layer was 
washed with brine. The organic layer was dried using anhydrous MgSO4, filtered and 
concentrated under reduced pressure. The crude residue was purified through column 
chromatography using hexane: ethyl acetate.
Ethyl (S)-2-(4-(5-(2-(2,3-dichlorophenoxy)propanamido)benzo[d]oxazol-2-
yl)phenoxy)acetate (18a): White powder (438 mg, 83%), 1H NMR (DMSO-d6) 10.31 (s, 
1H, NH), 8.08–8.03 (m, 3H, 3×CH), 7.66–7.64 (m, 1H, CH), 7.50–7.48 (m, 1H, CH), 7.29–
6.98 (m, 5H, 5×CH), 4.97 (q, J = 6.40 Hz, 1H, CH), 4.87 (s, 2H, -OCH2-), 4.13 (q, J = 7.20 
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Hz, 2H, -OCH2-), 1.58 (d, J = 6.80 Hz, 3H, CH3), 1.17 (t, J = 7.20 Hz, 3H, CH3). Purity 
99% (tR = 15.02). m.p. 144–145 C.
Ethyl(S)-2-(3-(5-(2-(2,3-dichlorophenoxy)propanamido)benzo[d]oxazol-2-
yl)phenoxy)acetate (18b): White powder (422 mg, 80%), 1H NMR (DMSO-d6) 10.35 (s, 
1H, NH), 8.09 (m, 1H, CH), 7.76 (d, J = 8.00 Hz, 1H, CH), 7.70 (d, J = 8.00 Hz, 1H, CH), 
7.62–7.61 (m, 1H, CH), 7.55–7.47 (m, 2H, 2×CH), 7.27 (t, J = 6.20 Hz, 1H, CH), 7.21–7.18 
(m, 2H, 2×CH), 7.02–7.00 (m, 1H, CH), 4.98 (q, J = 6.80 Hz, 1H, CH), 4.89 (s, 2H, -
OCH2-), 4.15 (q, J = 7.20 Hz, 2H, -OCH2-), 1.59 (d, J = 6.40 Hz, 3H, CH3), 1.18 (t, J = 6.80 
Hz, 3H, CH3). Purity 99% (tR = 13.28). m.p. 175–176 C.
Synthesis of 19: The ester 18 was subjected to ester hydrolysis using the general 
procedure described for 7.
(S)-2-(4-(5-(2-(2,3-Dichlorophenoxy)propanamido)benzo[d]oxazol-2-
yl)phenoxy)acetic acid (19a): White powder (440 mg, 88%), 1H NMR (DMSO-d6) 
10.36 (s, 1H, NH), 8.12 (d, J = 8.80 Hz, 2H, 2×CH), 8.08 (m, 1H, CH), 7.70 (d, J = 8.80 Hz, 
1H, CH), 7.50 (m, 1H, CH), 7.32 (t, J = 8.40 Hz, 1H, CH), 7.25 (m, 1H), 7.13 (d, J = 8.80 
Hz, 2H, 2×CH), 7.05 (d, J = 8.00 Hz, 1H, CH), 5.02 (q, J = 6.40 Hz, 1H, CH), 4.82 (s, 2H, -
OCH2-), 1.63 (d, J = 6.40 Hz, 3H, CH3). Purity 98% (tR = 12.64). m.p. 238–239 C.
(S)-2-(3-(5-(2-(2,3-Dichlorophenoxy)propanamido)benzo[d]oxazol-2-
yl)phenoxy)acetic acid (19b): White powder (430 mg, 86%), 1H NMR (DMSO-d6) 
13.07 (bs, 1H, COOH), 10.35 (s, 1H, NH), 8.09 (m, 1H, CH), 7.76–7.70 (m, 2H, 2×CH), 
7.59–7.46 (m, 3H, 3×CH), 7.26 (t, J = 8.00 Hz, 1H, CH), 7.21–7.14 (m, 2H, 2×CH), 7.01 (d, 
J = 8.00 Hz, 1H, CH), 4.98 (q, J = 6.40 Hz, 1H, CH), 4.79 (s, 2H, -OCH2-), 1.59 (d, J = 6.40 
Hz, 3H, CH3). Purity 97% (tR = 12.77). m.p. 191-dec C.
Prop-2-yn-1-yl (S)-2-(4-(5-(2-(2,3-dichlorophenoxy)propanamido)benzo[d]oxa-
zol-2-yl)phenoxy)acetate (20): Arylbenzoxazole 19a (1 mmol) was dissolved in dry 
DMF (5 mL) in an oven dried round bottom flask and cooled to 0 ºC. K2CO3 (2 mmol) was 
added to the cold solution and stirred well for ten minutes, followed by propargyl bromide 
80% solution in toluene (1.5 mmol) was added and stirred well at room temperature for 6 h. 
After completion, reaction was quenched with water and extracted with ethyl acetate (20 
mL) and organic layer was washed with brine. The organic layer was dried using MgSO4, 
filtered and concentrated under reduced pressure. The crude product was purified through 
column chromatography. White solid (435 mg, 81%), 1H NMR (DMSO-d6) 10.37 (s, 1H, 
NH), 8.12 (d, J = 8.80 Hz, CH, 2×CH), 8.08 (m, 1H, CH), 7.72–7.70 (d, J = 8.80 Hz, 1H, 
CH), 7.55 (d, J = 8.00 Hz, 1H, CH), 7.34–7.26 (m, 2H, 2×CH), 7.17 (d, J = 8.40 Hz, 2H, 
2×CH), 7.05 (d, J = 8.00 Hz, 1H, CH), 5.03–5.00 (m and s, 3H, CH, -OCH2-), 4.83 (s, 2H, -
OCH2-), 3.64 (bs, 1H, CH), 1.63 (d, J = 6.00 Hz, 3H, CH3). Purity 98% (tR = 14.69). m.p. 
132–133 C.
(S)-4-(5-(2-(2,3-Dichlorophenoxy)propanamido)benzo[d]oxazol-2-yl)-N-
hydroxybenzamide (21): The ester 8h (1 mmol) was dissolved in methanol and 
hydroxylamine hydrochloride (2 mmol) was added at 0 ºC and stirred well. KOH (3 mmol) 
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was added to the cold solution and stirred overnight at room temperature. After completion, 
the solvent was removed under reduced pressure and the residue was dissolved in water and 
extracted with ethyl acetate. The organic layer was washed with brine and dried using 
anhydrous MgSO4. Solvent was removed under reduced pressure and the product was 
purified using column chromatography. White powder (310 mg, 65%), 1H NMR (DMSO-d6) 
13.29 (bs, 1H, -OH), 10.37 (s, 1H, NH), 8.26 (d, J = 8.00 Hz, 2H, 2×CH), 8.11 (t, J = 8.40 
Hz, 3H, 3×CH), 7.74(d, J = 9.20 Hz, 1H, CH), 7.56 (d, J = 8.80 Hz, 1H, CH), 7.26 (t, J = 
8.00 Hz, 1H, CH), 7.20 (m, 1H, CH), 7.00 (d, J = 8.00 Hz, 1H, CH), 4.99 (q, J = 6.80 Hz, 
1H, CH), 1.59 (d, J = 6.80 Hz, 3H, CH3). Purity 98% (tR = 13.37). m.p. 253–254 C.
(S)-4-(5-(2-(2,3-Dichlorophenoxy)propanamido)benzo[d]oxazol-2-yl)benzoic 
acid (22): Ester 8h (1 mmol) was dissolved in THF:MeOH:H2O (3:1:1) at room 
temperature and NaOH (1 mmol) was added and stirred well for 2 h. After completion, the 
solvents were removed under reduced pressure. The crude residue was dissolved in water 
and pH was adjusted to 3−5 by the addition of 2N HCl and extracted with ethyl acetate. The 
organic layer was washed with brine and dried using anhydrous MgSO4. The crude acid was 
recrystallized using ethyl acetate and hexane. White powder (423 mg, 90%), 1H NMR 
(DMSO-d6) 10.43 (s, 1H, NH), 8.30 (d, J = 8.40 Hz, 2H, 2×CH), 8.15 (t, J = 9.00, 3H, 
3×CH), 7.79 (d, J = 8.80 Hz, 1H, CH), 7.61 (d, J = 8.80 Hz, 1H, CH), 7.32 (t, J = 8.20 Hz, 
1H, 1×CH), 7.26–7.24 (m, 1H, CH), 7.05 (d, J = 8.00 Hz, 1H, CH), 5.04 (q, J = 6.80 Hz, 1H, 
CH), 1.64 (d, J = 6.40 Hz, 3H, CH3). Purity 98% (tR = 13.33). m.p. 244 C.
(S)-2-(2,3-Dichlorophenoxy)-N-(2-(4-
(hydrazinecarbonyl)phenyl)benzo[d]oxazol-5-yl)propanamide (23): Hydrazine 
hydrate (3 mmol) was added to the stirred solution of 8h (1 mmol) in ethanol (10 mL) at 
room temperature and refluxed for 5 h. After completion, the solvent was removed under 
reduced pressure, water was added and extracted with ethyl acetate. The organic layer was 
washed with brine and dried using anhydrous MgSO4. The solvent was removed under 
reduced pressure and the crude mixture was purified through column chromatography. 
White powder (324 mg, 67%), 1H NMR (DMSO-d6) 10.41 (s, 1H, NH), 9.97 (s, 1H, NH), 
8.25 (d, J = 6.80 Hz, 2H, 2×CH ), 8.16 (m, 1H, CH), 8.03 (d, J = 6.80 Hz, 2H, 2×CH), 7.77 
(d, J = 9.2 Hz, 1H, CH), 7.60 (d, J = 8.40 Hz, 1H, CH), 7.32 (t, J = 7.60, 1H, CH), 7.25 (m, 
1H), 7.05 (d, J = 8.40 Hz, 1H, CH), 5.03 (q, J = 6.80 Hz, 1H, CH), 4.60 (bs, 2H, NH2), 1.58 
(d, J = 6.80 Hz, 3H, CH3). Purity 97% (tR = 10.37). m.p. 247–248 C.
(S)-2-(2,3-Dichlorophenoxy)-N-(2-(4-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-
yl)phenyl)benzo[d]oxazol-5-yl)propanamide (24): To the stirred solution of 23 (1 
mmol) in anhydrous DMF (2 mL), carbonyldiimidazole (1.2 mmol) and 
diisopropylethylamine (1.2 mmol) was added. The reaction mixture was stirred for 2 h at 
room temperature. The reaction mixture was diluted with water and extracted with ethyl 
acetate. The combined extract was washed with brine, dried using anhydrous MgSO4, 
filtered and concentrated. The residue was purified through colum chromatography (2−8% 
MeOH gradient in CH2Cl2) to give the title compound. White solid (336 mg, 66%), 1H 
NMR (DMSO-d6) 12.78 (s, 1H, NH), 10.44 (s, 1H, NH), 8.33 (d, J = 7.60 Hz, 2H, 2×CH), 
8.17(m, 1H, CH), 8.01 (d, J = 8.00 Hz, 2H, 2×CH), 7.78 (d, J = 5.20 Hz, 1H, CH), 7.61 (d, J 
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= 8.80 Hz, 1H, CH), 7.32 (t, J = 8.40 Hz, 1H, CH), 7.25 (m, 1H, CH), 7.06 (d, J = 8.00 Hz, 
1H, CH),, 5.04 (q, J = 6.80 Hz, 1H, CH), 1.64 (d, J = 6.00 Hz, 3H, CH3). Purity 99% (tR = 
13.05). m.p. 288-dec C.
(S,Z)-2-(2,3-Dichlorophenoxy)-N-(2-(4-(N’-
hydroxycarbamimidoyl)phenyl)benzo[d]oxazol-5-yl)propanamide (25): (S)-N-(2-
(4-cyanophenyl)benzo[d]oxazol-5-yl)-2-(2,3-dichlorophenox-y)propanamide 8f (1 mmol) 
was dissolved in anhydrous ethanol (5 mL) followed by hydroxylamine hydrochloride (3 
mmol) and triethylamine (6 mmol) was added. The reaction mixture was refluxed for 4 h 
and the solvent was removed under reduced pressure. The residue was suspended in water 
and extracted with DCM (20 mL). Organic layer was washed with brine and dried using 
anhydrous MgSO4. The solvent was removed under reduced pressure and the crude product 
was purified through column chromatography (2−8% MeOH gradient in CH2Cl2) to give the 
title compound. White solid (396 mg, 82%), 1H NMR (DMSO-d6) 10.34 (s, 1H, NH), 9.85 
(s, 1H, OH), 8.13–8.08 (m, 2H, 2×CH), 7.86–7.84 (m, 2H, 2×CH), 7.71–7.68 (m, 1H, CH), 
7.53–7.51 (m, 1H, CH), 7.28–7.18 (m, 3H, 3×CH), 7.00–6.98 (m, 1H, CH), 5.90 (s, 2H, 
NH2), 4.97 (m, 1H, CH), 1.57 (m, 3H, CH3). Purity 97% (tR = 14.97). m.p. 196–197 C.
(S)-2-(2,3-Dichlorophenoxy)-N-(2-(4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-
yl)phenyl)benzo-[d]oxazol-5-yl)propanamide (26): To the stirred solution of 25 (1 
mmol) in anhydrous DMF (2 mL), carbonyldiimidazole (1.2 mmol) and 
diisopropylethylamine (1.2 mmol) was added. The reaction mixture was stirred for 2 h at 
room temperature. The reaction mixture was diluted with water and extracted with ethyl 
acetate. The combined extract was washed with brine, dried using anhydrous MgSO4, 
filtered and concentrated. The residue was purified through colum chromatography (2−8% 
MeOH gradient in CH2Cl2) to give the title compound. White solid (321 mg, 61%), 1H 
NMR (DMSO-d6) 10.49 (s, 1H, NH), 9.60 (bs, 1H, NH), 8.32 (d, J = 8.40 Hz, 2H, 2×CH), 
8.15 (m, 1H, CH), 7.99 (d, J = 8.40 Hz, 2H, 2×CH), 7.72 (m, 1H, CH), 7.58 (m, 1H, CH), 
7.27 (t, J = 7.60 Hz, 1H, CH), 7.21 (m, 1H, CH), 7.02 (d, J = 8.40 Hz, 1H, CH), 5.03 (q, J = 
6.80 Hz, 1H, CH), 1.59 (d, J = 6.80 Hz, 3H, CH3). Purity 98% (tR = 13.04). m.p. 260 C.
(S)-N-(2-(4-(1H-Tetrazol-5-yl)phenyl)benzo[d]oxazol-5-yl)-2-(2,3-
dichlorophenoxy)propanamide (27): A mixture of (S)-N-(2-(4-
cyanophenyl)benzo[d]oxazol-5-yl)-2-(2,3-dichlorophenoxy)propanamide 8f (1 mmol), NaN3 
(2 mmol), and NH4Cl (2 mmol) in DMF (1.5 mL) was heated at 100 °C for 6 h. Solvent was 
removed under reduced pressure, water was added and extracted with ethyl acetate. The 
organic layer was washed with brine, dried using anhydrous MgSO4, filtered and 
concentrated under reduced pressure. The crude residue was purified through column 
chromatography. White solid (306 mg, 62%), 1H NMR (DMSO-d6) 11.11 (s, 1H, NH), 
10.38 (s, 1H, NH), 8.36–8.34 (m, 1H, CH), 8.22 (d, J = 5.80 Hz, 2H, 2×CH), 8.13 (m, 1H, 
CH), 7.90 (m, 1H, CH), 7.76–7.70 (m, 1H, CH), 7.59–7.50 (m, 1H, CH), 7.30–7.21 (m, 2H, 
2×CH), 7.00 (m, 1H, CH), 5.01 (m, 1H, CH), 1.59 (m, 3H, CH3). Purity 99% (tR = 12.25). 
m.p. 257 C.
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(S)-4-(5-(2-(2,3-Dichlorophenoxy)propanamido)benzo[d]oxazol-2-yl)benzamide 
(28): To the stirred solution of (S)-N-(2-(4-cyanophenyl)benzo[d]oxazol-5-yl)-2-(2,3-
dichlorophenoxy)prop-anamide 8f (1 mmol) in dry tert-butyl alcohol (4 mL/mmol), KOtBu 
(3 mmol), was added. The reaction mixture was stirred at room temperature for 12 h under a 
nitrogen atmosphere, and progress of the reaction was monitored by TLC. Upon completion, 
the reaction mixture was quenched with water and extracted with ethyl acetate. The organic 
layer was washed with brine, dried using anhydrous MgSO4 and solvent was removed under 
reduced pressure. The crude mixture was purified through column chromatography. White 
solid (253 mg, 54%), 1H NMR (DMSO-d6) 10.36 (s, 1H, NH), 8.21 (d, J = 8.00 Hz, 2H, 
2×CH), 8.12 (s, 2H, NH2), 8.03 (d, J = 8.00 Hz, 2H, 2×CH), 7.73 (d, J = 8.40 Hz, 1H, CH), 
7.55 (d, J = 8.40 Hz, 1H, CH), 7.51 (m, 1H, CH), 7.26 (t, J = 8.00 Hz, 1H, CH), 7.20 (m, 
1H), 7.00 (d, J = 8.40 Hz, 1H, CH) 4.98 (q, J = 6.80 Hz, 1H, CH), 1.59 (d, J = 6.80 Hz, 3H, 
CH3). Purity 98% (tR = 11.56). m.p. 232 C.
(S)-N-(2-(4-(Aminomethyl)phenyl)benzo[d]oxazol-5-yl)-2-(2,3-
dichlorophenoxy)propanamide (29): To a stirred solution of (S)-N-(2-(4-
cyanophenyl)benzo[d]oxazol-5-yl)-2-(2,3-dichloroph-enoxy)propanamide 8f ( 2.0 mmol) in 
THF: MeOH (15 mL), Boc2O (873 mg, 4.0 mmol) and NiCl2·6H2O (48 mg, 0.2 mmol) were 
added at 0 ºC and stirred for five minutes. After five minutes, NaBH4 (530 mg, 14.0 mmol) 
was added in small portions over 30 min followed by stirring at room temperature for 2h. 
The reaction mixture was filtered through celite and the filtrate was concentrated under 
reduced pressure. The crude residue was poured into 1N HCl and extracted with ethyl 
acetate. The organic layer was washed with brine and dried using anhydrous MgSO4. 
Solvent was removed under reduced pressure and crude reaction mixture was purified 
through column chromatography. Trifluoroacetic acid (1 mL) was added to the stirred 
solution of Boc protected amine (1 mmol) in dry DCM (5 mL) at 0 ºC. After 4 h, the 
reaction was quenched with a saturated NaHCO3 solution and extracted with DCM. The 
organic layer was washed with brine and dried using anhydrous MgSO4. The solvent was 
removed under reduced pressure and the product was recrystallized using ethyl acetate and 
hexane. White solid (305 mg, 67%), 1H NMR (DMSO-d6) 10.40 (s, 1H, NH), 8.14–8.10 (m, 
3H, 3×CH), 7.73 (d, J = 9.20 Hz, 1H, CH), 7.58–7.56 (m, 3H, 3×CH), 7.32 (t, J = 8.20 Hz, 
1H, CH), 7.26–7.24 (m, 1H, CH), 7.05 (d, J = 8.00 Hz, 1H, CH), 5.03 (q, J = 6.80 Hz, 1H, 
CH), 3.82 (s, 3H, -OCH3), 1.64–1.63 (d, J = 6.00 Hz, 3H, CH3). Purity 97% (tR = 14.63). 
m.p. 189-dec C.
(S)-2-(2,3-Dichlorophenoxy)-N-(2-(2-oxo-1,2-dihydropyridin-4-
yl)benzo[d]oxazol-5-yl)propanamide (30): To the stirred solution of 8b (1 mmol) in 
DMF, LiCl (5 mmol) and p-TSA (5 mmol) was added and stirred well for 2 h at 120 ºC. 
After completion, reaction was quenched with saturated NaHCO3 solution and extracted 
with ethyl acetate. The organic layer was washed with brine and dried using MgSO4. 
Solvent was removed under reduced pressure and crude residue was purified through column 
chromatography. White solid (341 mg, 77%), 1H NMR (DMSO-d6) 12.20 (bs, 1H, NH), 
10.30 (s, 1H, NH), 8.19 (s, 1H, CH), 8.02 (dd, J = 9.80 Hz, J = 2.20 Hz, 1H, CH), 7.98 (m, 
1H, CH), 7.61 (d, J = 9.20 Hz, 1H, CH), 7.46 (m, 1H, CH), 7.27 (t, J = 8.00 Hz, 1H, CH), 
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7.19 (m, 1H), 6.99 (d, J = 8.80 Hz, 1H, CH), 6.47 (d, J = 9.60 Hz, 1H, CH), 4.97 (q, J = 6.40 
Hz, 1H, CH), 1.58 (d, J = 6.80 Hz, 3H, CH3). Purity 97% (tR = 10.25). m.p. 240–241 C.
(S)-4-(5-(2-(2,3-Dichlorophenoxy)propanamido)benzo[d]oxazol-2-yl)pyridine1-
oxide (31): m-Chloroperoxybenzoic acid (2 mmol) was added to the stirred solution of 8a 
(1 mmol) in dry DCM at rt and stirred well for overnight. After completion, reaction was 
quenched with saturated NaHCO3 solution and extracted with DCM. The organic layer was 
washed with brine, dried using MgSO4, filtered and concentrated under reduced pressure. 
The crude product was purified through column chromatography. White solid (327 mg, 
74%), 1H NMR (DMSO-d6) 10.43 (s, 1H, NH), 8.38 (d, J = 6.80 Hz, 2H, 2×CH), 8.17 (m, 
1H, CH), 8.09 (d, J = 6.80 Hz, 2H, 2×CH), 7.78–7.76 (m, 1H, CH), 7.63–7.60 (m, 1H, CH), 
7.16–7.12 (m, 1H, CH), 7.06–7.02 (m, 1H, CH), 6.95–6.92 (m, 1H, CH), 5.00 (q, J = 6.80 
Hz, 1H, CH), 1.62 (d, J = 6.80 Hz, 3H, CH3). Purity 99% (tR = 10.80). m.p. 125-dec C.
(S)-2-(2-(Aminomethyl)phenoxy)-N-(2-(4-methoxyphenyl)benzo[d]oxazol-5-
yl)propanamide (32): The reaction was proceeded with 8u using the procedure, which 
used for the synthesis of 29. White solid (283 mg, 68%), 1H NMR (DMSO-d6) 11.10 (bs, 
1H, NH), 8.13–8.11 (d, J = 9.2 Hz, 2H, 2×CH), 8.02–8.01 (m, 1H, CH), 7.67 (d, J = 8.2 Hz, 
1H, CH), 7.54–7.51 (m, 1H, CH), 7.29–7.14 (m, 3H, 3×CH), 7.04–7.02 (m, 1H, CH), 6.93–
6.91 (m, 1H, CH), 5.06 (q, J = 6.80 Hz, 1H, CH), 3.71 (s, 3H, -OCH3), 1.62 (d, J = 6.80 Hz, 
3H, CH3). Purity 97% (tR = 14.31). m.p. 160–161 C.
(S)-N-(2-(4-Cyanophenyl)benzo[d]oxazol-5-yl)-2-(2-
hydroxyphenoxy)propanamide (33): Compound 8v (1 mmol) was dissolved in 10 mL 
EtOAc: MeOH (1:1) and 10% Pd/C (catalytic) was added and stirred well under a H2 
atmosphere for 3 h. After the successful completion, reaction mixture was filtered through 
celite and the filtrate was concentrated under reduced pressure. The crude product was 
purified through column chromatography. White solid (359 mg, 90%), 1H NMR (DMSO-d6) 
10.26 (s, 1H, NH), 9.29 (s, 1H, OH), 8.34 (d, J = 8.4 Hz, 2H, 2×CH), 8.22–8.21 (m, 1H, 
CH), 8.08 (d, J = 8.80 Hz, 2H, 2×CH), 7.81 (d, J = 8.80 Hz, 1H, CH), 7.68–7.66 (m, 1H, 
CH), 7.05–7.03 (d, J = 7.6 Hz, 1H, CH), 6.88–6.83 (m, 2H, 2×CH), 6.71–6.73 (m, 1H, CH), 
4.87 (q, J = 6.80 Hz, 1H, CH), 1.57 (d, J = 6.80 Hz, 3H, CH3). Purity 99% (tR = 11.10). m.p. 
185–186 C.
Methyl (S)-2-(2-bromo-3-formylphenoxy)propanoate (34): 2-Bromo-3-
hydroxybenzaldehyde (1 mmol) was added to the solution of (+)-methyl-D-lactate (1.38 
mmol) in anhydrous THF (6 mL) under a nitrogen atmosphere and the solution was cooled 
to 0 °C. PPh3 (1.20 mmol) was added portion wise and stirred for 10 min followed by the 
dropwise addition of DEAD (1.50 mmol) over 20 min. The reaction mixture was stirred for 
2 h at room temperature. After completion, the solvent was removed under reduced pressure 
and the crude mixture was purified through column chromatography using ethyl acetate/n-
hexane (10:90) to yield methyl ((S)-2-(2-bromo-3-formylphenoxy)propanoate (236 mg, 
83%) as a white solid.
Methyl (S)-2-(2-bromo-3-((methoxymethoxy)methyl)phenoxy)propanoate 
(35): Under a nitrogen atmosphere, NaBH4 (1.5 mmol) was added to the stirred solution of 
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((S)-2-(2-bromo-3-formylphenoxy)propanoate 34 (1 mmol) in ethanol at 0 ºC. After 1 h at 
room temperature, the reaction was quenched with a saturated NaHCO3 solution and 
extracted with ethyl acetate. The organic layer was washed with brine and dried using 
anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude product was 
dissolved in dry DCM and cooled to 0 ºC. DIPEA (5 mmol) was added, followed by 
dropwise addition of MOMCl (3 mmol) and stirred for overnight at room temperature. After 
completion, the reaction was quenched with saturated NH4Cl and extracted with DCM. The 
organic layer was dried using anhydrous MgSO4 and the solvent was removed under 
reduced pressure. The crude residue was purified through column chromatography. White 
solid (239 mg, 72%), 1H NMR (DMSO-d6) 7.32–7.28 (m, 1H, CH), 7.12–7.09 (m, 1H, CH), 
6.90–6.88 (m, 1H, CH), 5.06 (m, 1H, CH), 4.70 (bs, 3H, -OCH3), 4.61–4.51 (m, 4H, 2×-
OCH2-), 3.68 (s, 3H, -COOCH3), 1.55 (m, 3H, CH3).
Methyl (S)-2-(3-((methoxymethoxy)methyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxa-
borolan-2-yl)phenoxy)propanoate (36): To a solution of methyl (S)-2-(2-bromo-3-
((methoxymethoxy)methyl)phenoxy)propanoate 35 (400 mg, 1.145 mmol) in 1,4-dioxane (6 
mL) was added KOAc (483 mg, 4.923 mmol), Pin2B2 (349 mg, 1.37 mmol) and 
Pd(Ph3P)2Cl2 (80 mg, 0.114 mmol) under an argon atmosphere. The reaction flask was 
placed under vacuum and then backfilled with argon (two times). Then the reaction was 
stirred at 95 ºC for overnight. The solvent was removed under reduced pressure and the 
residue was suspended in water and extracted with ethyl acetate. The organic layer was 
washed with brine and dried over anhydrous MgSO4, filtered and concentrated. The crude 
product was purified through column chromatography using hexane/ethyl acetate. White 
solid (243 mg, 64%), 1H NMR (DMSO-d6) 7.28–7.24 (m, 1H, CH), 6.93–6.88 (m, 1H, CH), 
6.68–6.66 (m, 1H, CH), 4.90–4.86 (m, 1H, CH), 4.56 (bs, 4H, 2×-OCH2-), 4.47 (bs, 3H, -
OCH3), 3.67 (s, 3H, -COOCH3), 1.45 (m, 3H, CH3), 1.29 (bs, 12H, 4×CH3).
(S)-N-(2-(4-Cyanophenyl)benzo[d]oxazol-5-yl)-2-((1-hydroxy-1,3-dihydrobenzo-
[c][1,2]oxaborol-7-yl)oxy)propanamide (37): Ester 36 (1 mmol) was dissolved in 5 
mL THF: MeOH (2:3) and stirred at 0 ºC. LiOH (1.5 mmol) was added portion wise to the 
solution and stirred well at room temperature for 4 h. The solvents were removed under 
reduced pressure, crude residue was dissolved in ethyl acetate and 1N HCl was added until a 
pH of 4 was reached. The product was extracted with ethyl acetate and the organic extracts 
were combined, washed with brine, dried over anhydrous MgSO4. The solvent was removed 
under reduced pressure and crude acid was used in the next step without chromatographic 
purification. EDC·HCl (1.5 mmol) was added to the stirred solution of acid (1 mmol), amine 
5 (Ar = 4-CNPh, 1 mmol) in dry DMF at 0 ºC under nitrogen atmosphere. Reaction mixture 
was stirred well for overnight at room temperature. After completion of the reaction, excess 
water was added and extracted with ethyl acetate. The organic layer was washed with brine 
and dried using MgSO4. The solvent was removed under reduced pressure. The crude 
residue was purified through column chromatography give desired coupled product. To a 
solution of this MOM protected material (140 mg, 0.363 mmol) in THF (0.9 mL) 4 N HCl 
(0.43 mL, 18.1 mmol) was added. The reaction was stirred at room temperature for 4 h, 
upon completion ethyl acetate was added and extracted. The organic phase was washed with 
brine, dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The 
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crude product was purified through column chromatography using hexane/ethyl acetate. 
Brown solid (122 mg, 28%).1H NMR (DMSO-d6) 10.13 (s, 1H, NH), 9.20 (s, 1H, OH), 8.34 
(d, J = 8.4 Hz, 2H, 2×CH), 8.22 (m, 1H, CH), 8.08 (d, J = 8.40 Hz, 2H, 2×CH), 7.80 (d, J = 
9.2 Hz, 1H, CH), 7.70 (m, 1H, CH), 7.45 (m, 1H, CH), 7.04 (d, J = 7.60 Hz, 1H, CH), 6.93 
(d, J = 7.60 Hz, 1H, CH), 5.03 (q, J = 6.80 Hz, 1H, CH), 4.98 (s, 2H, -OCH2-), 1.62 (d, J = 
6.8 Hz, 3H, CH3). Purity 97% (tR = 11.27). m.p. hygroscopic.
Inhibition of MtbIMPDH.—The Ki,app values were determined by measuring the initial 
velocities at varying concentrations of the inhibitors (1–10,000 nM) with fixed 
concentrations of IMP (0.5 mM) and NAD+ (1.5 mM) and MtbIMPDH2 (20–50 nM). 
Inhibition of human IMPDH2 was assayed IMP using (0.25 mM) and NAD+ (0.060 mM) 
and hIMPDH2 (250 nM). Inhibition of human GMPR2 was assayed using GMP (0.050 
mM), NADPH (0.045 mM) and enzyme (100 nM). The assay buffer contained 50 mM 
TrisCl, pH 8.0, 100 mM KCl and 1 mM dithiothreitol.
The values of Ki,app were obtained using the equations (1) and (2)
vi = v0/  1 +   I / IC50 (1)
Ki,app =  IC50 –   E /2 (2)
where vi is the initial velocity in the presence of inhibitor and v0 is the initial velocity in the 
absence of the inhibitor. If the IC50 value is comparable to the enzyme concentration, the 
Morrison tight binding equation was used to determine Ki,app (3)
vi/v0 =  1 − E   +   I   + Ki,app   −   E   +   I   + Ki,app
2 −  4 E I
0.5
/ 2 E (3)
where [E] is the concentration of the enzyme. All the initial velocity measurements were 
performed in triplicates. The Ki,app values reported are the average of at least two 
independent experiments unless otherwise noted.
MIC determinations.—MICs were determined as previously described.9 MIC values were 
determined in at least triplicate according to the broth microdilution methods using 
compounds from DMSO stock solutions. Isoniazid was used as a positive control and 
DMSO was utilized as a negative control. Isolated Mtb cells (ATCC 27294) were cultured to 
an OD 0.2–0.3 in the required medium, then diluted to deliver approximately 1 × 104 
bacteria per well of a 96 well clear round-bottom plate. Plates were read after 1 week with 
an inverted enlarging mirror plate reader and graded as either growth or no growth. 
GAST/Fe medium (per liter) consisted of 0.3 g of Bacto Casitone (Difco), 4.0 g of dibasic 
potassium phosphate, 2.0 g of citric acid, 1.0 g of L-alanine, 1.2 g of magnesium chloride 
hexahydrate, 0.6 g of potassium sulfate, 2.0 g of ammonium chloride, 1.80 ml of 10 N 
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sodium hydroxide, and 10.0 ml of glycerol, 0.05% Tween 80 and 0.05 g of ferric ammonium 
citrate adjusted to pH 6.6. 7H9/glycerol/glucose/BSA/Tween medium consisted of 
Middlebrook 7H9 broth base supplemented per liter with 0.2% glucose, 0.2% glycerol, 0.5% 
BSA fraction V, 0.08% NaCl and 0.05% Tween 80. Cultures were supplemented with 200 
μM guanine as noted.
MtbIMPDH2 downregulation and susceptibility of SRMV2.6.—Mtb strains guaB2 
cKD (guaB2-B3 Tet-OFF attB::guaB3) and SRMV2.6, which carries guaB2Y487C, were 
cultured in Middlebrook 7H9 media (Difco) supplemented with 0.2% glycerol, Middlebrook 
oleic acid-albumin-dextrose-catalase (OADC) enrichment (Difco) and 0.05% Tween 80 
(7H9/Glycerol/OADC/Tween). Hygromycin (Hyg), kanamycin (Km) and gentamycin (Gm) 
were used in guaB2 cKD culture at final concentrations of 50, 25 and 2.5 μg/mL, 
respectively. ATc (Sigma) was used at concentrations up to 100 ng/mL. For pairwise 
combination (checkerboard) assays, a two-dimensional array of serial dilutions of test 
compound and ATc was prepared in 96-well plates, as previously described.11 MIC testing 
was carried out by broth microdilution using the AlamarBlue (AB, Invitrogen) assay 51, 52.
Mammalian Cell Culture.—Hep G2 cells (ATCC, purchased February 2017) were 
cultivated in EMEM supplemented with 10% heat inactivated FBS and 1X penicillin/
streptomycin under standard conditions (37 °C in a 5% CO2 humidified atmosphere). 
HEK293T, MCF7 and HELA cells were cultured in DMEM with 10% heat inactivated FBS 
and 1X penicillin/streptomycin. Active cell cultures routinely tested for presence of 
Mycoplasma (MycoAlert™ detection kit, Lonza) and confirmed to be Mycoplasma free.
LDH Cytotoxicity Assay.—All compounds were dissolved in DMSO and further diluted 
with culture medium before use in tissue culture assays (final DMSO concentrations were ≤ 
0.1%). To determine cytotoxicity, LDH release was measured with the LDH Cytotoxicity 
Assay Kit (Pierce) according to manufacturer’s protocol. Briefly, 96 well plates were seeded 
with 13,000 Hep G2 cells (all other cell lines seeded at 6,000 to 8,000 cells per well) and the 
cells were cultured for 24 h prior to drug treatment. The cells were incubated in 110 μL of 
EMEM containing compound or DMSO (vehicle only, control) for 24 h at 37°C. At least 
four wells from each plate were used as either ‘spontaneous’ LDH controls or as ‘maximum’ 
LDH controls per manufacturer’s instructions. Cytotoxicity was determined by measuring 
absorbance on a microplate reader. Data represent two independent experiments each 
performed in quadruplicate (n =8).
ADMET studies were performed by GVK Biosciences, (Hyderbad India).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations Used:
BSA bovine serum albumin
CBS cystathione β-synthetase
CDI carbonyl diimidazole
DCM dichloromethane
DEAD diethylazodicarboxylate
DIPEA diisopropylethylamine
EDC•HCl 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
EDG electron donating group
EWG electron withdrawing group
Gua guanine
HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate)
IMP inosine 5’-monophosphate
IMPDH2 inosine 5’-monophosphate dehydrogenase 2
LDH lactate dehydrogenase
m-CPBA meta-chloroperoxybenzoic acid
MIC minimum inhibitory concentration
Mtb Mycobacterium tuberculosis
NAD nicotinamide adenine dinucleotide
NMP N-methyl-2-pyrrolidone
p-TSA para-toluene sulfonic acid
SAR structure-activity relationship
TEA triethylamine
TFA trifluoroacetic acid
XMP xanthosine 5’-monophosphate
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Figure 1. 
Inhibitors of MtbIMPDH2. A) Structures of 1, 2 and 3. B) Crystal structure of 
MtbIMPDH2ΔCBS •IMP•3 (PDB 4ZQO)9. 3 is pink, IMP is blue, hydrogen bonds are 
shown in cyan, residues from the adjacent subunit are marked with ‘. C) Crystal structures of 
M. thermoresistible IMPDH2 in complex with IMP and cyclohexyl[4-(5-
isoquinolinylsulfonyl)-1-piperazinyl]methanone (VCC234718, PDB 5J5R, protein and IMP 
are spring green, inhibitor is forest green) 11, and N-1H-indazol-6-yl-3,5-dimethyl-1H-
pyrazole-4-sulfonamide (6Q9, PDB 5K4X, protein and IMP are gray, inhibitor is blue) 10. 
The structure of MtbIMPDH2ΔCBS •IMP•3 (PDB 4ZQO, protein and IMP are tan, 3 is 
pink)9 is also included. This figure was produced with UCSF Chimera 44.
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Figure 2. 
An overview of the SAR explored in this study.
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Figure 3. 
Correlation between antibacterial activity and enzyme inhibition for Q series compounds. 
Values from Table 4 and Makowska-Grzyska et al 9. Mtb H37Rv cultured in A) GAST 
medium and B) 7H9 medium.
Chacko et al. Page 33
J Med Chem. Author manuscript; available in PMC 2019 June 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. 
Knockdown of MtbIMPDH2 hypersensitizes Mtb to Q compounds. Regulated expression of 
guaB2 is achieved in a TET-OFF system, as previously described 11. Addition of 
anhydrotetracycline (ATc) represses expression of guaB2, decreasing the level of 
MtbIMPDH2 within the bacteria. ATc concentrations (ng/mL) are 0 (dark orange), 0.08 
(dark blue), 0.15 (green), 0.31 (sky blue), 0.62 (yellow), 1.25 (gray), 2.5 (orange) and 5 
(royal blue).
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Figure 5. 
Cytotoxicity of select Q compounds in HepG2 cells after 24 h.
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Scheme 1. 
Synthesis of various aryl benzoxazoles 8, thioamide 9, amine 11, imidazo[1,2-a]pyridine 13, 
methylene linked derivative 15 and N-arylated benzoxazoles 17a-b.a
aReagents and conditions: (a) ArCHO, DarcoKB, O2 (1 atm), xylene 140 ºC, 6–8 h, 70–
80%; (b) 10% Pd/C, H2 (1 atm), EtOAc:MeOH, 3 h, 85–94%; (c) PPh3, DEAD, (+)-methyl 
D-lactate, THF, 0 ºC to rt, 4 h, 85–90%, (d) LiOH, THF:MeOH, 4 h, 86–91%; (e) 5, 
EDC·HCl, DMF, 12 h, 62–79%. (f) Lawesson’s reagent, 1,4-dioxane, reflux, 2 h, 71%; (g) 1. 
DIBAL-H, DCM, −78 ºC, 1h, 89%, (h) 5 (Ar = 4-OMePh), NaBH(OAc)3, DCE, 1.5 h, 81%; 
(i) 4-OMePhC(O)CH2Br, NaHCO3, EtOH, reflux, 12 h, 88%; (j) SnCl2, EtOH:EtOAc, 
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reflux, 2 h; (k) 7 (R = 2,3-diCl), EDC·HCl, DMF, rt, 12 h, 60%; (l) 2-amino-4-nitrophenol, 
DABCO, NMP, 100 ºC, 24 h, 60%; (m) 10% Pd/C, H2, MeOH:EtOAc, 2–3 h; (n) 7 (R = 2,3-
diCl), EDC·HCl, DMF, rt, 12 h, 67%; (o) L-alanine, CuI, Cs2CO3, DMF, 90 ºC, 24 h; (p) 5 
(Ar = 4-CNPh), HATU, DMF, rt, 12 h, 45–54%.
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Scheme 2. 
Synthesis of derivatives 18a-b, 19a-b and 20-24.a
aReagents and conditions: (a) BrCH2COOEt, K2CO3, DMF, rt, 6 h, 80–83%; (b) LiOH, 
THF:MeOH, rt, 86–88%; (c) NH2OH·HCl, KOH, MeOH, rt, 12 h, 65%; (d) NaOH, 
THF:MeOH:H2O (3:1:1), 2 h, rt, 90%; (e) NH2NH2·H2O, EtOH, reflux, 5 h, 67%; (f) CDI, 
DIPEA, DMF, rt, 2 h, 66%; (g) CH≡CCH2Br, K2CO3, DMF, rt, 6 h, 81%.
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Scheme 3. 
Synthesis of derivatives 25-29 from 8f.a
aReagents and conditions: (a) NH2OH·HCl, Et3N, EtOH, reflux, 4 h, 82%; (b) CDI, DIPEA, 
DMF, rt, 2 h, 61%; (c) NaN3, NH4Cl, DMF, 100 ºC, 6 h, 62%; (d) t-BuOK, t-BuOH, 12 h, 
54%; (e) 1. NiCl2·6H2O, NaBH4, Boc2O, MeOH:THF, rt, 2 h, 2. TFA, DCM, rt, 4 h, 67%.
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Scheme 4. 
Synthesis of derivatives 30-33.a
aReagents and conditions: (a) LiCl, p-TSA, DMF, 120 ºC, 2 h, 77%; (b) m-CPBA, DCM, rt, 
12 h, 74%; (c) NiCl2·H2O, NaBH4, and then Boc2O, THF, MeOH, rt, 4 h; (d) TFA, DCM, 
68%; (e) 10% Pd/C, H2, MeOH:EtOAc, rt, 3 h, 90%.
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Scheme 5. 
Synthesis of benzoxaborole 37.a
aReagents and conditions: (a) (+)-Methyl D-lactate, DEAD, PPh3, THF, 0 ºC, 2 h, 83%; (b) 
NaBH4, EtOH, rt, 1 h; (c) MOMCl, DIPEA, DCM, rt, 12 h, 72%; (d) Pin2B2, Pd(Ph3P)2Cl2, 
KOAc, 1,4-dioxane, 95 ºC, 12 h, 64%; (e) LiOH, MeOH:THF, 4 h, 0 ºC; (f) 5 (Ar = 4-
CNPh), EDC·HCl, DMF, rt, 12 h; (g) 4N HCl, THF, 4 h, 28%.
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Table 1.
MtbIMPDH2ΔCBS Inhibition of Benzoxazole Derivatives Containing Various Aryl Substituents.
Cmpd Ar Ki,app (nM)a
MtbIMPDH2 hIMPDH2 hGMPR2
1 b See Figure 1A 150 ± 50 >5000 >5000
2 (e.g. 8a) b See Figure 1A 76 ± 27 >5000 >5000
3 b See Figure 1A 14 ± 3 >5000 >5000
30 4-pyridin-2-one 220 ± 6 >5000 >5000
31 4-Py-N-oxide 70 ± 19 >5000 >5000
8b 4-(2-OMe)-Py 12 ± 0.1 >5000 >5000
8c 3-(6-OMe)-Py 20 ± 4 >5000 >5000
8d 4-OMe-Ph 6.9 ± 3.9 >5000 >5000
8e 4-OCF3-Ph 4.3 ± 0.2 >5000 >5000
8f 4-CN-Ph 12 ± 3 2300 >5000
8g 4-F-Ph 35 ± 7 >5000 >5000
8h 4-PhCO2Me 96 ± 43 >5000 >5000
8i 4-OH-Ph 50 ± 17 >5000 >5000
8j 3-OH-Ph 85 ± 30 >5000 >5000
8k 2-OH-Ph 96 ± 21 >5000 >5000
18a 4-Ph-OCH2CO2Et 6.6 ± 0.4 >5000 >5000
20 4-Ph-OCH2CO2CH2CCH 12 ± 2 >5000 >5000
19a 4-Ph-OCH2CO2H 18 ± 3 >5000 >5000
18b 3-Ph-OCH2CO2Et 23 ± 1 >5000 >5000
19b 3-Ph-OCH2CO2H 55 ± 10 >5000 >5000
21 4-Ph-C(O)NHOH 630 ± 210 >5000 >5000
22 4-PhCO2H 360 ± 140 >5000 >5000
23 4-Ph-C(O)NHNH2 49 ± 6 >5000 >5000
24 2.3 ± 1.0 2900 >5000
25 39 ± 12 >5000 >5000
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Cmpd Ar Ki,app (nM)a
MtbIMPDH2 hIMPDH2 hGMPR2
26 46 ± 12 >5000 >5000
27 4-Ph-tetrazole 51 ± 2 >5000 >5000
28 4-Ph-C(O)NH2 64 ± 26 >5000 >5000
29 4-Ph-CH2NH2 240 ± 26 >5000 >5000
a.Values are the average and range of at least two independent determinations.
*Single determination.
b.Values from Makowska-Grzyska et al9.
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Table 2.
MtbIMPDH2ΔCBS Inhibition of Benzoxazole Derivatives Containing Various Phenyl Ether Substituents.
Cmpd R1 R2 R3 Ar Ki,app
a(nM)
MtbIMPDH2 hIMPDH2 hGMPR2
8l F F H 4-Py 55 ± 9 >5000 >5000
8m F F H 4-OMe-Ph 19 ± 2 >5000 >5000
8n F F H 4-OH-Ph 121 ± 21 >5000 >5000
8o F F H 3-(6-OMe)-Py 42 ± 17 >5000 >5000
8p F F H 4-CN-Ph 7.2 ± 2.5 2000 >5000
8q F F H 4-F-Ph 40 ± 3 >5000 >5000
8r F F F 4-CN-Ph 22 ± 11 >5000 >5000
8s CN H H 4-Py 76 ± 35 >5000 >5000
8t CN F H 4-Py 40 ± 2 >5000 >5000
8u CN H H 4-OMePh 33 ± 5 >5000 >5000
8v OBn H H 4-CN-Ph 43 ± 12 >5000 >5000
32 CH2NH2 H H 4-OMe-Ph 23 ± 9 >5000 >5000
33 OH H H 4-CN-Ph 36 ± 12 >5000 >5000
37 B(OH)OCH2 H 4-CN-Ph 370 ± 70 * >5000 >5000
a.Values are the average and range of at least two independent determinations.
*Single determination, error of the fit is listed.
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Table 3.
MtbIMPDH2ΔCBS Inhibition of Other Benzoxazole Derivatives.
Cmpd Structure
Ki,app
a(nM)
MtbIMPDH2 hIMPDH2 hGMPR2
9
27 ± 21 >5000 >5000
11
1290 ± 250* n.a. >5000
13
160 ± 4 >5000 >5000
15
100 ± 40 >5000 >5000
17a
9 ± 4 3300 >5000
17b
18 ± 3 >5000 >5000
a.Values are the average and range of at least two independent determinations.
*Single determination.
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Table 4.
Antitubercular activity of MtbIMPDH2 inhibitors against Mtb H37Rv. The number of independent 
determinations is shown in parentheses.
Compound
GAST/Fe
MIC (μM) a
7H9/ADC/Tween
MIC (μM) a
−Gua +Gua −Gua +Gua
1 b
5.3 ± 0.9
(3)
24 ± 16
(3)
10 ± 2
(3)
21 ± 4
(3)
2 (e.g. 8a) b 9.4 ± 3.0(2)
37
(1)
16 ± 6
(3)
28 ± 9
(2)
3 b
6.7 ± 3
(2)
50
(1)
12 ± 6
(3)
35 ± 15
(2)
8b 6.3 ± 0.0(2)
6.3 ± 0.0
(2)
3.5 ± 1.2
(2)
14 ± 5
(2)
8c 7 ± 2(3)
9 ± 7
(3)
6 ± 3
(3)
> 25
(3)
8d >50(2)
>50
(2)
>50
(2)
>50
(2)
8e >50(1)
>50
(1)
>50
(2)
>50
(2)
8f 4 ± 1(3)
5 ± 1
(3)
3 ± 1
(4)
6 ± 1
(4)
8g >50(2)
>50
(2)
>50
(2)
>50
(2)
8l 4 ± 2(2)
6.3 ± 0
(2)
1.9 ± 0.5
(2)
4 ± 3
(2)
8m 5 ± 2(3)
8 ± 4
(3)
4 ± 4
(4)
14 ± 7
(4)
8n 6(1)
19
(1)
7 ± 3
(2)
>30
(2)
8o 6 ± 5(2)
8 ± 7
(2)
>50
(5)
>50
(5)
8p 3 ± 1(3)
6.3 ± 0
(2)
1.5 ± 0.8
(6)
4 ± 3
(6)
8q >50(1)
>50
(2)
>50
(2)
>50
(2)
8r >50(2)
>50
(2)
>50
(5)
>50
(5)
8t 6 ± 4(2)
11 ± 2
(2)
4 ± 1
(2)
8 ± 2
(2)
8u 3.1 ± 0.0(2)
6.3 ± 0.0
(2)
1.2 ± 0.0
(2)
4.7 ± 0.0
(2)
9 37(1)
>50
(1)
>50
(2)
>50
(2)
17a 4 ± 3(2)
13 ± 9
(2)
3 ± 1
(2)
6 ± 1
(2)
17b 2 ± 1(2)
6 ± 0
(2)
1.0 ± 0.3
(2)
1.4 ± 0.3
(2)
18a 0.4 ± 0.0(2)
0.5 ± 0.1
(2)
0.2 ± 0.1
(2)
0.23 ± 0.16
(2)
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Compound
GAST/Fe
MIC (μM) a
7H9/ADC/Tween
MIC (μM) a
−Gua +Gua −Gua +Gua
18b 0.9 ± 0.2(2)
1.4 ± 0.2
(2)
1.6 ± 0.0
(2)
1.6 ± 0.0
(2)
19a 2 ± 1(4)
4 ± 2
(4)
9 ± 4
(5)
20 ± 10
(5)
20 0.4 ± 0.0(2)
1.4 ± 0.2
(2)
0.2 ± 0
(2)
0.4 ± 0
(2)
21 3 ± 1(4)
6 ± 1
(4)
30 ± 10
(5)
>50
(5)
22 4 ± 2(2)
5 ± 0
(2)
>25
(2)
>50
(2)
24 >50(2)
>50
(2)
>50
(2)
>50
(2)
25 25(1)
25
(1)
>50
(2)
>50
(2)
29 11 ± 2(2)
11 ± 2
(2)
25 ± 12
(2)
25 ± 12
(2)
32 9.4 ± 3.1(2)
16 ± 3
(2)
5.5. ± 0.8
(2)
9.4 ± 0.0
(2)
33 22 ± 3(2)
25 ± 0.0
(2)
9.4 ± 0.0
(2)
22 ± 3
(2)
a.
MICs determined after 1 week in culture.
b.Values from Makowska-Grzyska et al9. +Gua, 200 μM guanine.
J Med Chem. Author manuscript; available in PMC 2019 June 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chacko et al. Page 48
Table 5.
Antibacterial activity against SRMV2.6. H37Rv is the wild-type strain. b. SRMV2.6 contains MtbIMPDH2/
Y487C, which confers resistance to the isoquinoline sulfonamide inhibitor VCC23471811.
Compound
WTa
Ki,app
(nM)
Y487Cb
Ki,app
(µM)
Ratio
Ki,app
(Y487C)
/Ki,app (WT)
MIC (µM)c
H37Rv H37Rv(+ATc) SRMV2.6
1 150 ± 50 >50d >300 12.5 12.5 >100
17b 18 ± 3 1.1 ± 0.1 60 3.1 3.1 >100
18a 6.6 ± 0.4
~13f ~2000 3.1 3.1 3.1
22 360 ± 140 >15e >40 25 25 25
a.
Inhibition of purified wild-type MtbIMPDH2.
b.
Inhibition of purified MtbIMPDH2/Y487C
c.
Bacteria were cultured in 7H9/Glycerol/OADC/Tween and growth was measured with Alamar Blue as previously described 11, +ATc, 100 
ng/mL.
d.20% inhibition at 50 µM.
e.5-10% inhibition at 15 µM.
f.80% inhibition at 50 µM.
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